

INDEPENDENT AUDITOR'S REPORT

To The Members of Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited (the "Company"), which comprise the Balance Sheet as at 31 March 2026, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Cash Flows and the Statement of Changes in Equity for the year ended on that date, and notes to the financial statements, including a summary of material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2026, its profit, other comprehensive loss, its cash flows and the changes in equity for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibility for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Information Other than the Financial Statements and Auditor's Report Thereon

- The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Board's report, but does not include the financial statements, and our auditor's report thereon.
- Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.
- In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.
- If, based on the work we have performed on the other information that we obtained prior to the date of this auditor's report, we conclude that if there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Board of Directors for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including Ind AS specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Company's Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.

- Conclude on the appropriateness of Management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal financial controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books except for not complying with the requirement of audit trail as stated in (i)(vi) below.
 - c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, the Statement of Cash Flows and Statement of Changes in Equity dealt with by this Report are in agreement with the relevant books of account.
 - d) In our opinion, the aforesaid financial statements comply with the Ind AS specified under Section 133 of the Act.
 - e) On the basis of the written representations received from the directors as on 31 March 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2026 from being appointed as a director in terms of Section 164(2) of the Act.

- f) The modifications relating to the maintenance of accounts and other matters connected therewith, are as stated in paragraph (b) above.
- g) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls with reference to financial statements.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.
- i) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements - Refer Note 32 to the financial statements;
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - iv. (a) The Management has represented that, to the best of its knowledge and belief, other than as disclosed in the note 43 (f) to the financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(b) The Management has represented, that, to the best of its knowledge and belief, other than as disclosed in the note 43 (g) to the financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

- (c) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
 - v. The Company has not declared or paid any dividend during the year and has not proposed final dividend for the year.
 - vi. Based on our examination, which included test checks, the Company has used accounting softwares for maintaining its books of account for the year ended 31 March 2026 which have a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software except that:
 - (a) in respect of accounting software used for maintenance of point of sales records wherein the audit trail was not enabled at the database level to log any direct data changes during the period from 1 April 2025 to 9 September 2025. Consequent to this, we are unable to comment whether there were any instances of the audit trail feature being tampered with during this period.
- Further, during the course of our audit, we did not come across any instance of the audit trail feature being tampered with, in respect of accounting softwares for the period for which the audit trail feature was operating.
- Additionally, the audit trail that was enabled and operated for the year ended 31 March 2025, has been preserved by the Company as per the statutory requirements for record retention, as stated in Note 43(m) to the financial statements.
2. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No.008072S)


Ankit Daga
(Partner)

(Membership No. 512486)
(UDIN: 26512486WCEFXR4619)

Place: Bengaluru
Date: 28 April 2026

ANNEXURE "A" TO THE INDEPENDENT AUDITOR'S REPORT

(Referred to in paragraph 1(g) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Report on the Internal Financial Controls with reference to financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (the "Act")

Management's and Board of Directors' Responsibilities for Internal Financial Controls

The Company's Management and Board of Directors are responsible for establishing and maintaining internal financial controls with reference to financial statements based on the internal control with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Meaning of Internal Financial Controls with reference to financial statements

A Company's internal financial control with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with

Deloitte Haskins & Sells

generally accepted accounting principles. A Company's internal financial control with reference to financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with reference to financial statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial control with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls with reference to financial statements and such internal financial controls with reference to financial statements were operating effectively as at 31 March 2026, based on the criteria for internal financial control with reference to financial statements established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No.008072S)


Ankit Daga
(Partner)

(Membership No. 512486)
(UDIN: 26512486WCEFXR4619)

Place: Bengaluru
Date: 28 April 2026

ANNEXURE B TO THE INDEPENDENT AUDITOR'S REPORT

(Referred to in paragraph 2 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

In terms of the information and explanations sought by us and given by the Company and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that:

- (i)
 - (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of property, plant and equipment, capital work-in-progress and relevant details of right-of-use assets.
 - (B) The Company has maintained proper records showing full particulars of intangible assets.
 - (b) The Company has a program of verification of property, plant and equipment (except leasehold improvements), capital work-in-progress, and right-of-use assets so as to cover all the items in a phased manner over a period of 2 years, which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the program, certain property, plant and equipment, capital work-in-progress, and right-of-use assets were due for verification during the year and were physically verified by the management during the year. According to the information and explanations given to us, no material discrepancies were noticed on such verification.
 - (c) The Company does not have any immovable properties (other than immovable properties where the Company is the lessee and lease agreements are duly executed in favour of the Company) and hence reporting under clause (i)(c) of the Order is not applicable.
 - (d) The Company has not revalued any of its property, plant and equipment (including right-of-use assets) and intangible assets during the year.
 - (e) No proceedings have been initiated during the year or are pending against the Company as at 31 March 2026, for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.
- (ii)
 - (a) The inventories were physically verified during the year by the Management at reasonable intervals. In our opinion and according to the information and explanations given to us, the coverage and procedure of such verification by the Management is appropriate having regard to the size of the Company and the nature of its operations. No discrepancies of 10% or more in the aggregate for each class of inventories were noticed on such physical verification of inventories when compared with books of account.
 - (b) According to the information and explanations given to us, at any point of time of the year, the Company has not been sanctioned any working capital facility from banks or financial institutions on the basis of security of current assets, and hence reporting under clause (ii)(b) of the Order is not applicable.
 - (iii) The Company has not made any investments in, provided any guarantee or security to companies, firms, Limited Liability Partnerships or any other parties during the year. However, the Company granted unsecured loans to companies or other party during the year, in respect of which:

- a) The Company has provided unsecured loans during the year and stood guarantee in earlier years, details of which are as below:

Particulars	Loans (INR Lakhs)	Guarantees (INR Lakhs)
A. Aggregate amount granted / provided during the year		
- Subsidiary	162.50	Nil
- Others	86.53	Nil
B. Balance outstanding as at balance sheet date in respect of above cases:*		
- Subsidiary	793.17	428.46
- Others	251.63	Nil

*The amounts reported are at gross amounts, without considering provisions made.

- b) The terms and conditions of the grant of all the above-mentioned loans and guarantees provided, during the year are, in our opinion, prima facie, not prejudicial to the Company's interest.
- c) The Company has granted loans which is payable on demand. During the year the Company has demanded partial amount of such loan. Having regard to the fact that the repayment of principal or payment of interest has been demanded and received by the Company, in our opinion the repayments of principal amounts and receipts of interest are regular. (Refer reporting under clause(iii)(f) below).
- d) According to information and explanations given to us and based on the audit procedures performed, in respect of loans granted by the Company, there is no overdue amount remaining outstanding as at the balance sheet date.
- e) None of the loans granted by the Company have fallen due during the year.
- f) The Company has granted loans which are repayable on demand details of which are given below:

Name of the entity	All Parties (Amount in Lakhs)	Promoters (Amount in Lakhs)	Related Parties (Amount in Lakhs)
Aggregate of loans			
- Repayable on demand (A)	1,044.80	-	793.17
- Agreement does not specify any terms or period of repayment (B)	-	-	-
Total of (A+B)	1,044.80	-	793.17
Percentage of loans to the total loans	100.00%	-	75.92%

- (iv) The Company has complied with the provisions of Sections 185 and 186 of the Companies Act, 2013 in respect of loans granted, investments made and guarantees and securities provided, as applicable.

Deloitte Haskins & Sells

- (v) The Company has not accepted any deposit or amounts which are deemed to be deposits. Hence reporting under clause (v) of the Order is not applicable.
- (vi) The maintenance of cost records has been specified by the Central Government under section 148(1) of the Companies Act, 2013 in respect of services rendered. We have broadly reviewed the books of account maintained by the Company pursuant to the Companies (Cost Records and Audit) Rules, 2014, as amended, prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Companies Act, 2013, and are of the opinion that, prima facie, the prescribed cost records have been made and maintained by the Company. We have, however, not made a detailed examination of the cost records with a view to determine whether they are accurate or complete.
- (vii) In respect of statutory dues:
- (a) Undisputed statutory dues, including Goods and Service tax, Provident Fund, Employees' State Insurance, Income-tax, Custom duty, cess and other material statutory dues applicable to the Company have generally been regularly deposited by it with the appropriate authorities. As explained to us by the management, there were no dues payable in respect of Sales Tax, Service Tax, Excise duty, and Value Added Tax during the year.

There were no undisputed amounts payable in respect of Goods and Services tax, Provident Fund, Employees' State Insurance, Income-tax, Custom duty, cess and other material statutory dues in arrears as at 31 March 2026, for a period of more than six months from the date they became payable.

- (b) Details of statutory dues referred in sub-clause (a) above which have not been deposited as on 31 March 2026 on account of disputes are given below:

Name of Statute	Nature of dues	Forum where dispute is pending	Period which amount relates to the (financial year)	Amount involved (INR Lakhs)	Amount remaining unpaid (INR Lakhs)
Andhra Pradesh Value Added Tax Act and rules 2005	Value Added Tax	Deputy Commissioner (CT)	2013-14 to 2015-16	16.99	8.50
Income Tax Act, 1961	Income tax	Commissioner of Income Tax Appeals	2016-17	3.17	Nil
Finance Act, 1994	Service Tax	Commissioner of Central Tax	2014-15 to 2017-18	39.80	38.81

- (viii) There were no transactions relating to previously unrecorded income that were surrendered or disclosed as income in the tax assessments under the Income Tax Act, 1961 (43 of 1961) during the year.

Deloitte Haskins & Sells

- (ix)
 - (a) In our opinion, the Company has not defaulted in the repayment of loans or other borrowings or in the payment of interest thereon to any lender during the year.
 - (b) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
 - (c) To the best of our knowledge and belief, in our opinion, term loans availed by the Company were, applied by the Company during the year for the purposes for which the loans were obtained.
 - (d) On an overall examination of the financial statements of the Company, funds raised on short-term basis have, on prima facie, not been used during the year for longterm purposes by the Company.
 - (e) On an overall examination of the financial statements of the Company, the Company has not taken any fund from any entity or person on account of or to meet the obligations of its subsidiaries.
 - (f) The Company has not raised any loans during the year on the pledge of securities held in its subsidiaries. The Company does not have any joint ventures or associate companies.
- (x)
 - (a) The Company has not issued any of its securities (including debt instruments) during the year and hence reporting under clause (x)(a) of the Order is not applicable.
 - (b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause (x)(b) of the Order is not applicable to the Company.
- (xi)
 - (a) To the best of our knowledge, no fraud by the Company and no material fraud on the Company has been noticed or reported during the year.
 - (b) To the best of our knowledge, no report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and upto the date of this report.
 - (c) As represented to us by the Management, there were no whistle blower complaints received by the Company during the year and upto the date of this report.
- (xii) The Company is not a Nidhi Company and hence reporting under clause (xii) of the Order is not applicable.
- (xiii) In our opinion, the Company is in compliance with Section 177 and 188 of the Companies Act, 2013, where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed in the financial statements etc. as required by the applicable accounting standards.
- (xiv)
 - (a) In our opinion the Company has an adequate internal audit system commensurate with the size and the nature of its business.
 - (b) We have considered, the internal audit reports issued to the Company during the year and covering the period upto 31 March 2026 and the draft of the internal

audit reports issued after the balance sheet date covering the period 1 April 2025 to 31 March 2026 for the period under audit.

- (xv) In our opinion, during the year, the Company has not entered into any non-cash transactions with any of its directors or directors of its holding company, subsidiary companies or persons connected with such directors and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.
- (xvi) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause (xvi)(a), (b) and (c) of the Order is not applicable.

The Group does not have any Core Investment Company (CIC) as part of the group and accordingly reporting under clause (xvi)(d) of the Order is not applicable.
- (xvii) The Company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors of the Company during the year.
- (xix) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- (xx) The Company has fully spent the required amount towards Corporate Social Responsibility (CSR) and there are no unspent CSR amount for the year requiring a transfer to a Fund specified in Schedule VII to the Companies Act or special account in compliance with the provision of sub-section (6) of section 135 of the said Act. Accordingly, reporting under clause (xx) of the Order is not applicable for the year.

For **Deloitte Haskins & Sells**
Chartered Accountants
(Firm's Registration No.008072S)


Ankit Daga
(Partner)

(Membership No. 512486)
(UDIN: 26512486WCEFXR4619)

Place: Bengaluru
Date: 28 April 2026

Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited

CIN: U73100AP1995PTC020491

Balance sheet as at 31 March 2026

All amounts in INR lakhs, unless otherwise stated

Particulars	Note	As at 31 March 2026	As at 31 March 2025
Assets			
Non-current assets			
Property, plant and equipment	4.1	8,044.89	8,465.62
Right-of-use assets	34	2,212.76	2,456.17
Capital work-in-progress	4.2	4.31	3.78
Other intangible assets	5	24.58	26.58
Financial assets			
Investments	6	9,166.12	9,166.12
Other financial assets	12	403.20	386.34
Income tax assets (net)	31	1,068.78	487.46
Deferred tax assets (net)	31	296.24	480.57
Other non-current assets	13	103.86	134.81
Total non-current assets		21,324.74	21,607.45
Current assets			
Inventories	7	578.04	508.47
Financial assets			
Investments	6	8.62	8.08
Trade receivables	8	3,804.68	2,618.11
Cash and cash equivalents	9	118.41	67.15
Bank balances other than cash and cash equivalents above	10	-	21.00
Loans	11	1,044.80	974.92
Other financial assets	12	723.29	573.36
Other current assets	13	197.56	283.77
Total current assets		6,475.40	5,054.86
Total assets		27,800.14	26,662.31
Equity and liabilities			
Equity			
Equity share capital	14	1,078.58	1,078.58
Other equity	15	14,844.98	13,536.19
Total equity		15,923.56	14,614.77
Liabilities			
Non-current liabilities			
Financial liabilities			
Borrowings	16	1,266.00	1,809.24
Lease liabilities	34	3,569.70	3,821.25
Other financial liabilities	18	37.00	37.00
Provisions	19	992.76	756.65
Total non-current liabilities		5,865.46	6,424.14
Current liabilities			
Financial liabilities			
Borrowings	16	984.70	1,174.18
Lease liabilities	34	189.01	167.83
Trade payables	17	-	-
- Total outstanding dues of micro and small enterprises		660.21	264.41
- Total outstanding dues of creditors other than micro and small enterprises		2,427.70	2,347.13
Other financial liabilities	18	1,086.51	1,138.04
Provisions	19	82.39	-
Other current liabilities	20	580.60	531.81
Total current liabilities		6,011.12	5,623.40
Total equity and liabilities		27,800.14	26,662.31

The accompanying notes form an integral part of these financial statements

As per our report of even date attached

for Deloitte Haskins & Sells

Chartered Accountants

Firm registration number: 008072S

Ankit D.
Partner
Membership No: 512486
Bengaluru
Date: 28 April 2026



for and on behalf of the Board of Directors of

Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited

Caush
Dr. P. Ramesh Babu
Managing Director
DIN: 01879436
Vijayawada
Date: 28 April 2026

MS. Rama Mohan Rao
MS. Rama Mohan Rao
Chairman and Director
DIN: 02356742
Vijayawada
Date: 28 April 2026

Pavitra Prasad Hunswadkar
Pavitra Prasad Hunswadkar
Company Secretary
Membership No: 471646
Vijayawada
Date: 28 April 2026



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
CIN: U73100AP1995PTC020491
Statement of profit and loss for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

Particulars	Note	For the year ended 31 March 2026	For the year ended 31 March 2025
Income			
Revenue from operations	21	28,031.68	25,800.33
Other income	22	236.13	260.13
Total income		28,267.81	26,060.46
Expenses			
Purchases of medicines and medical consumables	23	5,795.00	5,159.97
Changes in inventories	24	(69.57)	(4.41)
Professional fee to consultant doctors	25	6,268.17	5,725.05
Laboratory outsourcing charges	26	277.56	235.56
Employee benefits expense	27	8,135.92	7,145.11
Finance costs	28	589.51	619.26
Depreciation and amortisation expenses	29	1,258.55	1,442.14
Other expenses	30	3,913.93	3,885.49
Total expenses		26,169.07	24,208.17
Profit before exceptional items and tax		2,098.74	1,852.29
Exceptional items	30.3	251.41	-
Profit before tax		1,847.33	1,852.29
Tax expense/ (benefit)	31		
Current tax		330.61	271.27
Current tax for earlier years		12.68	(11.52)
Deferred tax		187.49	310.52
Total tax expense		530.78	570.27
Profit for the year		1,316.55	1,282.02
Other comprehensive loss			
Items that will not be reclassified subsequently to profit or loss		(10.95)	(106.29)
Remeasurement of net defined benefit liability		3.19	30.95
Income tax relating to items that will not be reclassified to profit or loss		(7.76)	(75.34)
Total other comprehensive loss		1,308.79	1,206.68
Total comprehensive income for the year			
Earnings per share (equity share of face value of INR 10 each)	33		
Basic		12.21	11.89
Diluted		12.21	11.89

The accompanying notes form an integral part of these financial statements

As per our report of even date attached

for Deloitte Haskins & Sells
Chartered Accountants
Firm registration number: 008072S

Ankit Datta
Partner
Membership No.: 512486
Bengaluru
Date: 28 April 2026



for and on behalf of the Board of Directors of
Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited

Ramesh Babu
Dr. P. Ramesh Babu
Managing Director
DIN: 01879436
Vijayawada
Date: 28 April 2026

Pavitra Pramod Hunswadkar
Pavitra Pramod Hunswadkar
Company Secretary
Membership No.: 473646
Vijayawada
Date: 28 April 2026

M.S. Rama Mohan Rao
M.S. Rama Mohan Rao
Chairman and Director
DIN: 02356742
Vijayawada
Date: 28 April 2026



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
CIN: U73100AP1995PTC020491
Statement of Cash flow statement for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Cash flow from operating activities		
Profit for the year	1,847.33	1,852.29
<i>Adjustments for non cash and non operating items:</i>		
Depreciation and amortisation expenses	1,258.55	1,442.14
Finance costs	589.51	619.26
Allowances for credit losses on financial assets	173.74	(114.41)
Profit on sale of investment (net)	(0.54)	(0.11)
Share of profit in limited liability partnership	(74.32)	(6.42)
Interest income	(100.25)	(85.04)
Loss on disposal of property, plant and equipment (net)	13.80	0.17
Impact of lease modification	-	(14.64)
Operating cash flows before movements in working capital	3,707.82	3,693.24
Working capital adjustments		
Changes in inventories	(69.57)	(4.41)
Changes in trade receivables	(1,360.31)	(654.04)
Changes in other financial assets	(66.09)	(250.70)
Changes in other assets	58.09	71.24
Changes in trade payables	476.37	(373.35)
Changes in other financial liabilities	104.98	101.42
Changes in provisions	307.55	(13.45)
Changes in other liabilities	48.79	113.04
Cash generated from operating activities	3,207.64	2,682.99
Taxes paid, net of refund received	(924.58)	(123.56)
Net cash generated from operating activities (A)	2,283.06	2,559.43
Cash flows from investing activities		
Acquisition of property, plant and equipment, intangibles and capital work-in-progress	(778.78)	(768.69)
Proceeds on disposal of property, plant and equipment	5.59	1.74
Redemption of (Investment in) subsidiaries (net)	-	(456.06)
(Investments in)/proceeds from sale of mutual funds (net)	-	(0.42)
Movement in other bank balances and restricted deposits	(39.02)	11.00
Loan to subsidiary and others (net of loan repayment)	(69.88)	(168.92)
Share of profit in limited liability partnership	74.32	6.42
Interest received	68.25	29.52
Net cash used in investing activities (B)	(739.52)	(1,345.41)
Cash flow from financing activities		
Payment of lease liabilities	(519.50)	(520.96)
Finance cost paid	(237.10)	(288.97)
Long term secured loan availed	-	725.00
Long term secured loan repaid	(781.88)	(853.20)
Current borrowings (repaid) availed, net	(207.15)	(328.74)
Borrowing availed from subsidiary	390.00	76.65
Repayment of borrowings to subsidiary	(136.65)	-
Net cash used in financing activities (C)	(1,492.28)	(1,190.22)
Net increase/ (decrease) in cash and cash equivalents (A-B+C)	51.26	23.80
Cash and cash equivalents at the beginning of the year	67.15	43.35
Cash and cash equivalents at the end of the year (refer Note 9)	118.41	67.15

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Components of cash and cash equivalents		
Cash on hand	30.10	11.23
Balances with banks - in current accounts	88.31	23.92
Balances with banks - Deposits with original maturity of less than three months	-	10.00
Total	118.41	67.15



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
CIN: U73100AP1995PTC028491
Statement of Cash flow statement for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

Changes in liabilities arising from financing activities for the year ended 31 March 2026

Particulars	As at 01 April 2025	Movement during the year					As at 31 March 2026
		Cash inflows	Cash outflow	Additions/ Modifications	Non cash changes	Finance costs	
Non-current borrowings (including current maturities)	2,997.56	390.00	(1,362.78)	-	(13.13)	262.91	2,274.55
Lease liabilities	3,989.08	-	(519.50)	(37.47)	-	326.60	3,758.71
Total	6,986.63	390.00	(1,882.29)	(37.47)	(13.13)	589.51	6,033.26

Changes in liabilities arising from financing activities for the year ended 31 March 2025

Particulars	As at 01 April 2024	Movement during the year					As at 31 March 2025
		Cash inflows	Cash outflow	Additions/ Modifications	Non cash changes	Finance costs	
Non-current borrowings (including current maturities)	3,392.34	801.65	(1,470.91)	-	-	274.47	2,997.56
Lease liabilities	3,820.25	-	(520.96)	345.00	-	344.79	3,989.08
Total	7,212.59	801.65	(1,991.87)	345.00	-	619.26	6,986.63

The accompanying notes form an integral part of these financial statements

As per our report of even date attached

for Deloitte Haskins & Sells
Chartered Accountants
Firm registration number: 0080725

Ankit Das
Partner
Membership No. 512486
Bengaluru
Date 28 April 2026



for and on behalf of the Board of Directors of
Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited

Dr. P. Ramesh Babu
Managing Director
DIN: 01879436
Vijayawada
Date 28 April 2026

Pavitra Pramod Hunsawadkar
Company Secretary
Membership No: A73646
Vijayawada
Date : 28 April 2026

M.S. Rama Mohan Rao
Chairman and Director
DIN: 02356742
Vijayawada
Date : 28 April 2026



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
CIN: U73100AP1995PTC020491
Statement of changes in equity for the period ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

A. Equity share capital

Particulars	Note	Number of equity shares	Amount
Balance as at 1 April 2024	14	1,07,85,825.00	1,078.58
Changes in equity share capital during 2024-25			-
Balance as at 31 March 2025	14	1,07,85,825.00	1,078.58
Changes in equity share capital during 2025-26			-
Balance as at 30 March 2026		1,07,85,825.00	1,078.58

B. Other equity

Particulars	Reserves and surplus (Refer Note 15)			Items of other comprehensive income (Refer Note 15)		Total other equity attributable to equity holders of the Company
	Securities premium	Retained earnings	Capital redemption reserve	Re measurement of net defined benefit liability/ (asset), net of tax		
Balance as at 1 April 2024	7,454.54	4,893.26	40.00	(58.29)		12,329.51
Profit for the year		1,282.02			1,282.02	1,282.02
Other comprehensive income for the year, net of tax				(75.34)		(75.34)
Balance as at 31 March 2025	7,454.54	6,175.28	40.00	(133.62)		13,536.19
Balance as at 1 April 2025	7,454.54	6,175.28	40.00	(133.62)		13,536.19
Profit for the year		1,316.55		(7.76)		1,316.55
Other comprehensive income for the year, net of tax				(141.39)		(7.76)
Balance as at 31 March 2026	7,454.54	7,491.83	40.00			14,844.98

The accompanying notes form an integral part of these financial statements

As per our report of even date attached

for Deloitte Haskins & Sells
Chartered Accountants
Firm registration number 0080725



Asst. Mgr.
Firm No. 0080725
Membership No. : 512486
Bengaluru
Date : 28 April 2026

for and on behalf of the Board of Directors of
Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited

[Signature]
M.S. Rama Mohan Rao
Chairman and Director
DIN: 02356742
Vijayawada
Date : 28 April 2026



[Signature]
Pavitra Pramod Husewadkar
Company Secretary
Membership No. : A73646
Vijayawada
Date : 28 April 2026

Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

1. **Company overview**
Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited ("the Company") is a company domiciled in India, with its registered office at Vijayawada, Andhra Pradesh. The Company is engaged in the business of rendering medical and healthcare services, retail pharmacies, participating in clinical studies and conducting training programs and services primarily in Vijayawada and Guntur. Aster DM Healthcare Limited is the Holding Company.
2. **Basis of preparation**
- A. **Statement of compliance**
These financial statements have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as per the Companies (Indian Accounting Standards) Rules, 2015, as amended, and the relevant amended rules prescribed under Section 133 of the Companies Act, 2013 (the 'Act'), read with relevant rules issued thereunder.
Pursuant to Rule 6 of the Companies (Accounts) Rules, 2014 (Amended Rules), the Company has not presented consolidated financial statements as its Parent Company (Aster DM Healthcare Limited) is incorporated in India and presenting the consolidated financial statements as required by the Companies Act, 2013.
These financial statements were authorised for issue by the Company's Board of Directors on 28 April 2026.
Details of the Company's material accounting policies are included in Note 3.
- B. **Functional and presentation currency**
These financial statements are presented in Indian Rupees (INR), which is also the Company's functional currency. All amounts are presented in Indian Rupees in lakhs and are rounded off to two decimals, unless otherwise stated.
- C. **Basis of measurement**
The financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair values at the end of each reporting period, as explained in the accounting policies below.
- D. **Use of estimates and judgements**
In preparing these financial statements, the Management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income, and expenses. Actual results may differ from these estimates.
Estimates and underlying assumptions are reviewed by the Management on an ongoing basis. Revisions to accounting estimates are recognised prospectively.
Information about judgements, assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment during the year ended 31 March 2026 is included in the following notes:
 - Note 3.1, 3.2, 4 and 5 - Measurement of useful life and residual value of property, plant and equipment and intangible assets;
 - Note 6 - Impairment of investment in subsidiaries and others;
 - Note 3.11 and 31 - Recognition of deferred tax asset: availability of future taxable profit against which tax losses carried forward can be used;
 - Note 3.6 and 32 - Recognition and measurement of provisions and contingencies: key assumptions about the likelihood and magnitude of an outflow of resources;
 - Note 3.9 and 34 - Leases;
 - Note 3.5, 19 and 36 - Measurement of defined benefit obligations: key actuarial assumptions;
 - Note 3.4, 8, 11 and 39 - Impairment of financial assets;
- E. **Measurement of fair values**
A number of the Company's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities. The Company has an established control framework with respect to the measurement of fair values.
Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:
 - Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities;
 - Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
 - Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).
When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.
The Company recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.
Further information about the assumptions made in measuring fair values is included in the following notes:
 - Financial instruments and
 - Fair value of property, plant and equipment and intangible assets.
- F. **Recent accounting pronouncements**
Ministry of Corporate Affairs ("MCA") notified new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time.
On May 9, 2025, MCA notified the amendments to Ind AS 21 - Effects of Changes in Foreign Exchange Rates. These amendments aim to provide clearer guidance on assessing currency exchangeability and estimating exchange rates when currencies are not readily exchangeable. The amendments are effective for annual periods beginning on or after April 1, 2025. The Company has assessed that there is no significant impact on its financial statements.
In August 2025, MCA notified the following amendments:
Ind AS 1, Presentation of Financial Statements, Applicable w.e.f. April 1, 2025 - The amendment relates to classification of liabilities as current or non-current and non-current liabilities with covenants. In the context of classifying a liability as current, it removes the requirement of existence of a right to defer settlement for at least 12 months after the reporting date and instead requires that the said right should exist on the reporting date and have substance. The amendment also introduces guidance on classification of liabilities with covenants. The Company has no impact of these amendments on its classification criteria of current and non-current liabilities.
Ind AS 7, Statement of Cash Flows and Ind AS 107, Financial Instruments: Disclosures, applicable w.e.f. April 1, 2025 - The amendment in Ind AS 7 requires to inform users of financial statements of the existence of supplier finance arrangements and explain the nature of the arrangements, the carrying amount of liabilities and the range of payment due dates. Ind AS 107 has been amended to add supplier finance arrangements as a factor that may cause concentration of liquidity risk. The Company has reviewed the amendment and based on its evaluation has determined that it does not have any significant impact on its financial statements.
Ind AS 12, International Tax Reform: Pillar Two Model Rules applicable immediately - The amendments provide a temporary mandatory relief from deferred tax accounting for top-up tax and disclose that they have applied the relief. The Company has reviewed the amendment and based on its evaluation has determined that it does not have any significant impact on its financial statements.



3. Material accounting policies

3.1 Property, plant and equipment

i. Recognition and measurement

Items of property, plant and equipment are measured at cost, which includes capitalised borrowing costs, less accumulated depreciation and accumulated impairment losses, if any. Cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.

The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labour, any other costs directly attributable to bringing the item to working condition for its intended use, and estimated costs of dismantling and removing the item and restoring the site on which it is located.

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of property, plant and equipment.

Any gain or loss on disposal of an item of property, plant and equipment is recognised in the statement of profit and loss.

ii. Subsequent expenditure and derecognition

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. The gain or loss arising on the disposal or retirement of an asset is determined as the difference between the net disposal proceeds and the carrying amount of the asset and is recognised in the statement of profit and loss.

iii. Depreciation

Depreciation on property, plant and equipment are provided on the straight-line method over the useful lives of the assets estimated by the Management. Depreciation for assets purchased/sold during a period is proportionately charged. Leasehold improvements are amortized over the lease term or useful lives of assets, whichever is lower. The estimated useful lives of items of property, plant and equipment for the current and comparative years are as follows:

Class of assets	Useful life (in years)
Office equipment	5
Medical equipment*	10-13
Motor vehicles*	8-10
Computer equipment including servers and networks	3-6
Furniture and fixtures*	5-10
Electrical equipment	10

* For the above-mentioned classes of assets, the Company believes that the useful lives as given above best represent the useful lives of these assets based on internal assessment and supported by technical advice, where necessary, which is different from the useful lives as prescribed under Part C of Schedule II of the Companies Act, 2013.

Depreciation method, useful lives and residual values are reviewed at each financial year-end and adjusted if appropriate.

iv. Capital work-in-progress

Amounts paid towards the acquisition of property, plant and equipment outstanding as of each reporting date are recognized as capital advance and the cost of property, plant and equipment not ready for intended use before such date are disclosed under capital work-in-progress.

Commencement of Depreciation related to property, plant and equipment classified as Capital work-in-progress (CWIP) involves determining when the assets are available for their intended use. The criteria the Company uses to determine whether CWIP are available for their intended use involves subjective judgments and assumptions about the conditions necessary for the assets to be capable of operating in the intended manner.

3.2 Intangible assets

Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortisation and accumulated impairment losses. Intangible assets are amortised over their respective individual estimated useful lives on a straight-line basis, commencing from the date the asset is available to the Company for its use and is included in depreciation and amortisation expenses in the statement of profit and loss. The estimated useful life and amortisation method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. The estimated useful life of software is 4 years.

The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition and other economic factors (such as the stability of the industry and known technological advances) and the level of maintenance expenditures required to obtain the expected future cash flows from the asset.

An intangible asset is derecognised on disposal, or when no future economic benefits are expected from use or disposal. Gains or losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset, are recognised in the statement of profit and loss when the asset is derecognised.

3.3 Inventories

Inventories are measured at the lower of cost and net realisable value. The cost of inventories comprises purchase price, and other cost incurred in bringing the inventories to their present location and condition. The Company uses the weighted average method to determine the cost of inventory consisting of medicines and medical consumables.

Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs necessary to make the sale. The comparison of cost and net realisable values is made on an item-by-item basis.



3.4 Impairment

I. Impairment of financial assets

The Company recognises loss allowances for expected credit losses (ECL) on financial assets measured at amortised cost.

At each reporting date, the Company assesses whether financial assets carried at amortised cost are credit impaired. A financial asset is 'credit impaired' when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

The Company always measures the loss allowance for trade receivables at an amount equal to lifetime ECL. The expected credit losses on trade receivables are estimated using a provision matrix by reference to past default experience of the debtors and an analysis of the debtors' current financial position, adjusted for factors that are specific to the debtors, general economic conditions of the industry in which the debtors operate, and an assessment of both the current as well as the forecast direction of conditions at the reporting date.

In all cases, the maximum period considered when estimating expected credit losses is the maximum contractual period over which the Company is exposed to credit risk.

Measurement of expected credit losses

Expected credit losses are a probability weighted estimate of credit losses. Credit losses are measured as the present value of all cash shortfalls (i.e., the difference between the cash flows due to the Company in accordance with the contract and the cash flows that the Company expects to receive).

Presentation of allowance for expected credit losses in the balance sheet

Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount of the assets.

Write-off

The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Company determines that the debtor does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write off.

II. Impairment of non-financial assets

The Company's non-financial assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated to determine the extent of impairment loss, if any.

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset).

Intangible assets and property, plant and equipment are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. For the purpose of impairment testing, the recoverable amount is the higher of the fair value less cost to sell and the value-in-use is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the CGU to which the asset belongs.

If such assets are considered to be impaired, the impairment to be recognized in the statement of profit and loss is measured by the amount by which the carrying value of the assets exceeds the estimated recoverable amount of the asset.

An impairment loss is reversed in the statement of profit and loss if there has been a change in the estimates used to determine the recoverable amount. The carrying amount of the asset is increased to its revised recoverable amount, provided that this amount does not exceed the carrying amount that would have been determined (net of any accumulated amortization or depreciation) had no impairment loss been recognized for the asset in prior years.

3.5 Employee benefits

Short-term employee benefits

Employee benefits payable wholly within twelve months of receiving employee services are classified as short-term employee benefits. These benefits include salaries and wages, bonus and ex-gratia. Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognised for the amount expected to be paid e.g., under short-term cash bonus, if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the amount of obligation can be estimated reliably.

Post-employment benefits

Defined contribution plans

A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions and will have no legal or constructive obligation to pay further amounts. The Company makes specified monthly contributions towards Government administered provident fund scheme. Obligations for contributions to defined contribution plans are recognised as an employee benefit expense in the statement of profit and loss in the periods during which the related services are rendered by employees.

Defined benefit plans

Under a defined benefit plan, it is the Company's obligation to provide agreed benefits to the employees.

The calculation of defined benefit obligation is performed annually by a qualified actuary using the projected unit credit method.

Re-measurements of the net defined benefit liability, which comprise actuarial gains and losses are recognised in other comprehensive income (OCI) in the period in which they occur. Remeasurements of the net defined benefit liability (asset) recognised in other comprehensive income shall not be reclassified to the statement of profit and loss in a subsequent period. However, the Company transfers those amounts recognised in other comprehensive income within equity. The Company determines the net interest expense on the net defined benefit liability for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period to the then-net defined benefit liability, taking into account any changes in the net defined benefit liability during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognised in the statement of profit and loss.

Compensated absences

Pursuant to the applicable provisions of the Occupational Safety, Health and Working Conditions Code, 2020 and rules thereunder, the Company provides for leave encashment payable to eligible workers. The liability for unutilized earned leave is recognised as at the reporting date based on applicable wage rates, and is recognised in the period in which employees render services. As the benefit is expected to be settled within 12 months, it is classified as a short-term employee benefit, measured on an undiscounted basis, and presented under current liabilities.

3.6 Provisions (other than employee benefits)

A provision is recognised if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

A contract is considered to be onerous when the expected economic benefits to be derived by the Company from the contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision for an onerous contract is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before such a provision is made, the Company recognises any impairment loss on the assets associated with that contract.



- 3.7 Revenue**
The Company generates revenue from rendering of hospital services (hospital and medical services), revenue from sale of pharmacy, revenue from canteen services, revenue from consultancy services and other operating income. Revenue from Contracts with Customers (Ind AS 115), establishes a comprehensive framework for determining whether, how much and when revenue is recognised. Under Ind AS 115, revenue is recognised when a customer obtains control of the goods or services in an amount that reflects the consideration which the Company expects to receive in exchange for those products or services. In calculating the variable considerations, the Company considers the nature and coverage through insurance and other parties, the history of adjustments and rejections, and the probability of rejections, discounts, rebates, price concessions, or other similar items. The impact of these considerations is reflected as adjustments to revenue.

Disaggregation of revenue

The Company disaggregates revenue from hospital services (hospital and medical services), revenue from sale of pharmacy, revenue from canteen services, revenue from consultancy services and other operating income. The company further disaggregates revenue from hospital and medical services based on category of customers (cash and credit) and based on nature of treatment (In-patient and Out-patient). The Company believes that this disaggregation best depicts how the nature, amount, timing and certainty of Company's revenues and cash flows are affected by industry, market and other economic factors.

Contract balances

The Company classifies the right to consideration in exchange for sale of services where invoice is raised as trade receivables, where invoice has not been raised as unbilled revenue and advance consideration as advance from customers.

Performance obligations and revenue recognition policies

Revenue is measured based on the consideration specified in a contract with a customer. The Company recognises revenue when it transfers control over a good or service to a customer. The following details provide information about the nature and timing of the satisfaction of performance obligations in contracts with customers, including significant payment terms, and the related revenue recognition policies.

(a) Revenue from hospital and medical services

The Company's revenue from hospital and medical services comprises of income from hospital services.

Revenue from inpatient hospital services is recognised as revenue when the related services are rendered (i.e. satisfied over the period of time) and the same is actually received by the patients unless significant future uncertainties exist. Revenue from outpatient hospital services is recognised as revenue at a point in time when patient has actually received the service. Revenue is also recognised in relation to the services rendered to the patients who are undergoing treatment/ observation on the balance sheet date to the extent of the services rendered. Revenue is recognised net of discounts, concessions given to the patients and estimated disallowances for patients covered under insurance.

Unbilled receivable represents value to the extent of hospital and medical services are rendered to the patients who are undergoing treatment/ observation on the balance sheet date and is not billed as at the balance sheet date.

(b) Revenue from sale of pharmacy

Revenue from sale of pharmacy within the hospital premises is recognised when the control in the goods are transferred to the customer (i.e. at a point in time) and no significant uncertainty exists regarding the amount of the consideration that will be derived from the sale of the goods and regarding its collection. The amount of revenue recognised is net of sales returns, taxes and duties, wherever applicable.

(c) Other operating income

The Company's revenue from other operating income comprises primarily of revenue from medical courses conducted at the hospital and income from revenue sharing agreements.

(d) Revenue from canteen services

Revenue from canteen services is recognised at a point in time when control is transferred.

3.8 Foreign currency transactions

Transactions in foreign currencies are recorded in the functional currency of the Company at the exchange rates at the dates of the transactions or an average rate if the average rate approximates the actual rate at the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Non-monetary assets and liabilities that are measured at fair value in a foreign currency are translated into the functional currency at the exchange rate when the fair value was determined. Non-monetary assets and liabilities that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction. Exchange differences are recognised in the statement of profit and loss.

3.9 Leases

Determining whether an arrangement contains a lease

At inception of an arrangement, it is determined whether the arrangement is or contains a lease. At inception or on reassessment of the arrangement that contains a lease, the payments and other consideration required by such an arrangement are separated into those for the lease and those for other elements on the basis of their relative fair values.

i. Company as a lessee

The Company accounts for each lease component within the contract as a lease separately from non-lease components of the contract and allocates the consideration in the contract to each lease component on the basis of the relative stand-alone price of the lease component and the aggregate stand-alone price of the non-lease components.

The Company recognises right-of-use asset representing its right to use the underlying asset for the lease term of the lease commencement date. The cost of the right-of-use asset measured at inception shall comprise of the amount of the initial measurement of the lease liability adjusted for any lease payments made at or before the commencement date less any lease incentives received, plus any initial direct costs incurred and an estimate of costs to be incurred by the lessee in dismantling and removing the underlying asset or restoring the underlying asset or site on which it is located. The right-of-use asset is subsequently measured at cost less any accumulated depreciation, accumulated impairment losses, if any and adjusted for any remeasurement of the lease liability. The right-of-use asset is depreciated using the straight-line method from the commencement date over the shorter of lease term or useful life of right-of-use asset. The estimated useful lives of right-of-use assets are determined on the same basis as those of property, plant and equipment. Right-of-use assets are tested for impairment whenever there is any indication that their carrying amounts may not be recoverable. Impairment loss, if any, is recognised in the statement of profit and loss.

The Company measures the lease liability at the present value of the lease payments that are not paid at the commencement date of the lease. The lease payments are discounted using the interest rate implicit in the lease, if that rate can be readily determined. If that rate cannot be readily determined, the Company uses incremental borrowing rate. The lease payments shall include fixed payments, variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date, residual value guarantees, exercise price of a purchase option where the Company is reasonably certain to exercise that option and payments of penalties for terminating the lease, if the lease term reflects the lessee exercising an option to terminate the lease. The lease liability is subsequently remeasured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments made and remeasuring the carrying amount to reflect any reassessment or lease modifications or to reflect revised in-substance fixed lease payments. The Company recognises the amount of the remeasurement of lease liability due to modification as an adjustment to the right-of-use asset and statement of profit and loss depending upon the nature of modification. Where the carrying amount of the right-of-use asset is reduced to zero and there is a further reduction in the measurement of the lease liability, the Company recognises any remaining amount of the re-measurement in the statement of profit and loss.

The Company has elected not to apply the requirements of Ind AS 116, Leases, to short-term leases of all assets that have a lease term of 12 months or less. The lease payments associated with these leases are recognised as an expense on a straight-line basis over the lease term.

Variable rents that do not depend on an index or rate are not included in the measurement of the lease liability and the right-of-use asset. The related payments are recognised as an expense in the period in which the event or condition that triggers those payments occurs and are included in the line "Other expenses" in the statement of profit and loss.



3.9 Leases (continued)

ii. Company as a lessor

At the inception of the lease the Company classifies each of its leases as either an operating lease or a finance lease. Whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee, the contract is classified as a finance lease. All other leases are classified as operating leases. The Company recognises lease payments received under operating leases as income on a straight-line basis over the lease term. In case of a finance lease, finance income is recognised over the lease term based on a pattern reflecting a constant periodic rate of return on the lessor's net investment in the lease.

Amounts due from lessees under finance leases are recognised as receivables at the amount of the Company's net investment in the leases. When the Company is an intermediate lessor, it accounts for its interests in the head lease and the sub-lease separately. It assesses the lease classification of a sub-lease with reference to the right-of-use asset arising from the head lease, not with reference to the underlying asset. If a head lease is a short-term lease to which the Company applies the exemption described above, then it classifies the sub-lease as an operating lease.

If an arrangement contains lease and non-lease components, the Company applies Ind AS 115 Revenue from contracts with customers to allocate the consideration in the contract.

3.10 Recognition of dividend income, interest income or interest expense

(a) Dividend income is recognised in the statement of profit and loss on the date on which the right to receive payment is established.

(b) Interest on deployment of surplus funds is recognized using the time proportionate method, based on the transactional interest rates.

(c) Profit share of partnership firm on accrual basis.

(d) Interest income or expense is recognised using the effective interest method.

The 'effective interest rate' is the rate that exactly discounts estimated future cash payments or receipts through the expected life of the financial instrument to the gross carrying amount of the financial asset or the amortised cost of the financial liability.

In calculating interest income and expense, the effective interest rate is applied to the gross carrying amount of the asset (when the asset is not credit-impaired) or to the amortised cost of the liability.

3.11 Income tax

Income tax comprises current and deferred tax. It is recognised in statement of profit and loss except to the extent that it relates to an item recognised directly in equity or in other comprehensive income.

i. Current tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax reflects the best estimate of the tax amount expected to be paid or received after considering the uncertainty, if any, related to income taxes. It is measured using tax rates (and tax laws) enacted or substantively enacted by the reporting date.

Current tax assets and current tax liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis or simultaneously.

A provision is recognised for those matters for which the tax determination is uncertain but it is considered probable that there will be a future outflow of funds to a tax authority. The provisions are measured at the best estimate of the amount expected to become payable. The assessment is based on the judgement of tax professionals within the Company supported by previous experience in respect of such activities and in certain cases based on specialist independent tax advice.

ii. Deferred tax

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the corresponding tax bases used for taxation purposes. Deferred tax assets are recognised for carry forward of unused tax losses and tax credits to the extent that it is probable that future taxable profit will be available against which such losses and credits can be utilised. Deferred tax assets are

recognised to the extent that it is probable that future taxable profits will be available against which they can be utilised. The existence of unused tax losses is strong evidence that future taxable profit may not be available. Therefore, in case of a history of recent losses, the Company recognises a deferred tax asset only to the extent that it has sufficient taxable temporary differences or there is convincing other evidence that sufficient taxable profit will be available against which such deferred tax asset can be realised. Deferred tax assets - unrecognised or recognised, are reviewed at each reporting date and are recognised/ reduced to the extent that it is probable no longer probable respectively that the related tax benefit will be realised.

Deferred tax is measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on the laws that have been enacted or substantively enacted by the reporting date. The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Company expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously.

3.12 Borrowings and Borrowings cost

Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortised cost. Any difference between the proceeds (net of transaction costs) and the redemption value is recognised in the statement of profit and loss over the period of the borrowings using the effective interest rate method. Borrowings are classified as current liabilities unless the Company has an unconditional right to defer settlement of the liability for at least 12 months after the reporting date.

Borrowing costs are interest and other costs (including exchange differences relating to foreign currency borrowings) to the extent that they are regarded as an adjustment to interest costs) incurred in connection with the borrowing of funds. Borrowing costs directly attributable to acquisition or construction of an asset which necessarily take a substantial period of time to get ready for their intended use are capitalised as part of the cost of that asset until such time as the asset is substantially ready for their intended use or sale. Other borrowing costs are recognised as an expense in the period in which they are incurred.

3.13 Financial instruments

i. Recognition and initial measurement

Trade receivables issued are initially recognised when they are originated. All other financial assets and financial liabilities are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

A financial asset or financial liability is initially measured at fair value, except for trade receivables that do not have a significant financing component which are measured at transaction price. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss - FVTPL) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognised immediately in statement of profit and loss.

ii. Classification and subsequent measurement

Financial assets

On initial recognition, a financial asset is classified as either at amortised cost, FVTPL or fair value through other comprehensive income (FVOCI).

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Company changes its business model for managing financial assets.

A financial asset is measured at amortised cost if it meets both of the following conditions:

- the asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and

- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investment's fair value in OCI (designated as FVOCI - equity investment). This election is made on an investment-by-investment basis.

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL. This includes all derivative financial assets. On initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost or at FVOCI as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.



3.13 Financial instruments (continued)

Financial assets: business model assessment

The Company makes an assessment of the objective of the business model in which a financial asset is held at investment level because this best reflects the way the business is managed and information is provided to management. The information considered includes:

- the stated policies and objectives for each of such investments and the operation of those policies in practice. These include whether Management's strategy focuses on earning contractual interest income, maintaining a particular interest rate profile, matching the duration of the financial assets to the duration of any related liabilities or expected cash outflows or realising cash flows through the sale of the assets;
- the risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;
- the frequency, volume and timing of sales of financial assets in prior periods, the reasons for such sales and expectations about future sales activity;

Transfers of financial assets to third parties in transactions that do not qualify for derecognition are not considered sales for this purpose, consistent with the Company's continuing recognition of the assets.

Financial assets that are held for trading or are managed and whose performance is evaluated on a fair value basis are measured at FVTPL.

Financial assets: Assessment whether contractual cash flows are solely payments of principal and interest

For the purposes of this assessment, "principal" is defined as the fair value of the financial asset on initial recognition. "Interest" is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g., liquidity risk and administrative costs), as well as a profit margin.

In assessing whether the contractual cash flows are solely payments of principal and interest, the Company considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of contractual cash flows such that it would not meet this condition. In making this assessment, the Company considers:

- contingent events that would change the amount or timing of cash flows;
- terms that may adjust the contractual coupon rate, including variable interest rate features;
- prepayment and extension features; and
- terms that limit the Company's claim to cash flows from specified assets (e.g., non-recourse features).

Financial assets: Subsequent measurement and gains and losses

Financial assets at FVTPL	These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in statement of profit and loss.
Financial assets at amortised cost	These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in statement of profit and loss. Any gain or loss on derecognition is recognised in statement of profit and loss.
Equity investments at FVOCI	These assets are subsequently measured at fair value. Dividends are recognised as income in statement of profit and loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognised in OCI and are not reclassified to statement of profit and loss.

Financial liabilities: Classification, subsequent measurement and gains and losses

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as FVTPL if it is classified as held for trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in statement of profit and loss.

Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in statement of profit and loss. Any gain or loss on derecognition is also recognised in statement of profit and loss.

iii. Derecognition

Financial assets

The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

If the Company enters into transactions whereby it transfers assets recognised on its balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets, the transferred assets are not derecognised.

Financial liabilities

The Company derecognises a financial liability when its contractual obligations are discharged or cancelled, or expire. The Company also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability based on the modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in statement of profit and loss.

iv. Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the balance sheet when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

3.14 Earnings / (Loss) per share

The basic earnings / (loss) per share (EPS) is computed by dividing the net profit / (loss) after tax for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year.

Diluted earnings per share is computed by dividing the profit/loss after tax (including the post tax effect of extraordinary items, if any) as adjusted for dividend, interest and other charges to expense or income (net of any attributable taxes) relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares.

Dilutive potential equity shares are deemed converted as of the beginning of the period unless issued at a later date. In computing diluted earnings per share, only potential equity shares that are dilutive, i.e., which reduces earnings per share or increases loss per share are included. The dilutive potential equity shares are adjusted for the proceeds receivable had the shares been actually issued at fair value (i.e. average market value of the outstanding shares). Dilutive potential equity shares are determined independently for each period presented. The number of equity shares and potentially dilutive equity shares are adjusted for share splits/reverse share splits and bonus shares, as appropriate.

3.15 Cash-flow statement

Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, investing and financing activities of the Company are segregated.

3.16 Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and on hand and short-term deposits with an original maturity of three months or less which are subject to insignificant risk of changes in value.

3.17 Segment reporting

Ind AS 108 "Operating Segments" (Ind AS 108) establishes standards for the way that public business enterprises report information about operating segments and related disclosures about products and services, geographic areas, and major customers. Based on the "management approach" as defined in Ind AS 108, Operating segments are to be reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker (CODM). The Board of directors of the Company. The CODM evaluates the Company's performance and allocates resources on overall basis. The Company's sole operating segment is therefore, Hospital and Medical Services.

3.18 Operating cycle

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

3.19 Exceptional items

An item of income or expense which by its size, nature or incidence requires disclosure in order to improve an understanding of the performance of the Company is treated as an exceptional item and disclosed separately in the financial statements.



Dr. Ramesh Curdare and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

4 Property, plant and equipment and capital work-in-progress

Particulars	Leasehold Improvements (Refer Notes (b) below)	Medical equipment	Electrical equipment	Office equipment	Computer equipment including servers and networks	Furniture and fixtures	Motor Vehicles	Total
Gross carrying value								
Balance as at 1 April 2024	6,083.39	7,436.20	1,451.75	1,027.92	417.33	634.76	371.17	17,422.52
Additions	17.47	832.07	74.26	39.85	48.58	27.48	14.80	1,054.51
Disposals	(24.62)	-	(0.37)	-	(1.93)	-	(30.46)	(57.38)
Balance as at 31 March 2025	6,076.24	8,268.27	1,525.64	1,067.77	463.98	662.24	355.51	18,419.65
Balance as at 1 April 2025	6,076.24	8,268.27	1,525.64	1,067.77	463.98	662.24	355.51	18,419.65
Additions	26.40	383.95	145.29	28.67	38.50	10.29	9.14	642.25
Disposals	-	(30.46)	(6.22)	(29.99)	(75.08)	-	(31.84)	(173.59)
Balance as at 31 March 2026	6,102.64	8,621.76	1,664.72	1,066.45	427.41	672.53	332.81	18,888.32
Accumulated depreciation								
Balance as at 1 April 2024	2,193.54	3,660.09	1,028.09	911.78	264.13	505.47	222.86	8,785.96
Charge for the year	177.54	671.73	130.94	38.40	76.22	96.65	32.22	1,223.70
Eliminated on disposals	(23.35)	-	(0.20)	-	(1.93)	-	(30.15)	(55.63)
Balance as at 31 March 2025	2,347.73	4,331.82	1,158.83	950.18	338.42	602.12	224.93	9,954.03
Balance as at 1 April 2025	2,347.73	4,331.82	1,158.83	950.18	338.42	602.12	224.93	9,954.03
Charge for the year	176.13	623.76	70.50	41.63	67.27	32.69	32.44	1,044.42
Eliminated on disposals	(19.10)	(4.28)	(4.28)	(29.84)	(75.04)	-	(26.77)	(155.03)
Balance as at 31 March 2026	2,523.86	4,936.48	1,225.05	961.97	330.65	634.81	230.60	10,843.42
As at 31 March 2026	3,578.78	3,685.28	439.67	104.48	96.76	37.72	102.20	8,044.89
As at 31 March 2025	3,728.51	3,936.45	366.81	117.59	125.56	60.12	130.58	8,465.62

a) For details of property, plant and equipment pledged, refer Note 16.

b) The Company has a hospital situated in Gimadala, Vijayawada which is located on land that has been taken on a sub-lease from Mrs. P. Mahesh Lakshmi, wife of the Managing Director who had taken it on lease from M/s Loyola College Society ("Society") vide a lease agreement dated 21 September 2004. The lease was initially taken for a period of 9 years and 11 months which was renewed for an additional period of 15 years and 1 month. This additional lease period expired on 31 January 2019.

At the time of entering into the initial lease, a separate intent letter dated 01 May 1994 was also issued by the Society stating that the Company will have an option to request for renewal of lease for a further period of 25 years from 31 January 2019 based on such terms and conditions as may be mutually agreed. In accordance with this intent letter, the Management made an application dated 03 July 2018 to the Society to extend the lease beyond 31 January 2019. However, the Society rejected this application and has issued a notice to the Company to vacate the premises and to hand over the entire building and structure to the Society.

Aggrieved by this, the Management filed a legal case against the Society and the matter is presently sub-judice. The Company had received injunction orders in its favour from the Court of the Hon'ble District Judge vide its order dated 28 June 2021. The Interlocutory Application (IA) was set aside pursuant to proceedings initiated by the Society before the Hon'ble High Court of Andhra Pradesh. Aggrieved thereby, an appeal was preferred before the Hon'ble Supreme Court of India, which restored the IA passed by the Trial Court and referred the matter to the Lok Adalat. However, the Company expressed its preference for adjudication of the dispute on merits. Accordingly, leave was granted by the Hon'ble Supreme Court, and the matter is currently pending adjudication before the Hon'ble Supreme Court of India. Based on legal advice, the Management is of the view that it has a good case to seek renewal of the lease and does not expect any impact of this matter on the future operations of the hospital.



Dr. Kamlesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

4 Property, plant and equipment and capital work-in-progress (Continued)

4.2 Capital work-in-progress (CWIP)

4.2.1 Ageing schedule of CWIP

Particulars	Amount in CWIP for a period of			Total
	Less than 1 year	1-2 years	More than 3 years	
Projects in progress				
As at March 31, 2026	0.71	3.60	-	4.31
As at March 31, 2025	3.78	-	-	3.78

4.2.2 As on the date of the balance sheet, there are no capital work-in-progress projects whose completion is overdue or has exceeded the cost compared to its revised plan.

5 Other Intangibles assets

Particulars	Computer software
Gross carrying value	200.04
Balance as at 1 April 2024	8.44
Additions	(42.15)
Disposals	166.33
Balance as at 31 March 2025	166.33
Balance as at 1 April 2025	15.72
Additions	(52.70)
Disposals	129.35
Balance as at 31 March 2026	
Accumulated amortisation	162.54
Balance as at 1 April 2024	19.20
Amortisation	(41.99)
Eliminated on disposals	139.75
Balance as at 31 March 2025	139.75
Balance as at 1 April 2025	16.89
Amortisation	(51.87)
Eliminated on disposals	104.77
Balance as at 31 March 2026	
Net carrying value	24.58
As at 31 March 2026	26.58
As at 31 March 2025	



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

6 Investments		As at	As at
Particulars	31 March 2026	31 March 2025	
Non-current investments, unquoted			
<i>Investments in equity instruments of subsidiaries (at cost)</i>			
Sanghamitra Hospitals Private Limited	8,856.74	8,856.74	
62,65,300 (31 March 2025: 62,65,300) equity shares of INR 10 each			
Aster Ramesh Duhita LLP	47.75	47.75	
51% of the total capital amounting to INR 47.75 lakhs			
(31 March 2025: 51% of the total capital amounting to INR 47.75 lakhs)			
Komali Fertility Centre LLP	40.00	40.00	
50% of the total capital amounting to INR 40 lakhs			
(31 March 2025: 50% of the total capital amounting to INR 40 lakhs)			
Komali Fertility Centre LLP-Ongole	51.00	51.00	
51% of the total capital amounting to INR 51 lakhs			
(31 March 2025: 51% of the total capital amounting to INR 51 lakhs)			
Adiran IB Healthcare Private Limited	160.63	160.63	
2,999,999 (31 March 2025: 2,999,999) equity shares of INR 10 each			
Aasraya HealthCare LLP	10.00	10.00	
51% of the total capital amounting to INR 663 lakhs			
(31 March 2025 and 31 March 2026 : INR 10 lakhs has been called upon and paid)			
Total	9,166.12	9,166.12	
Aggregate carrying amount of unquoted investments	9,166.12	9,166.12	
Current investments, quoted			
<i>Investment in Mutual Funds - Quoted investments (non-trade at fair value through profit or loss)</i>			
Reliance Equity Hybrid Fund- Segregated Portfolio - 1	1.82	1.73	
Nippon India Over Night Fund			
[1,260.54 (31 March 2025: 1,260.54) units]	6.80	6.35	
Nippon India Ultra Short Term Duration Fund			
[145.75 (31 March 2025: 145.75) units]	8.62	8.08	
Total	8.62	8.08	
Aggregate carrying amount of quoted investments	8.62	8.08	
Aggregate market value of quoted investments	8.62	8.08	
Aggregate amount of impairment in the value of investments			
7 Inventories		As at	As at
Particulars	31 March 2026	31 March 2025	
<i>(Valued at lower of cost and net realisable value)</i>			
Medicines and consumables	578.04	508.47	
Total	578.04	508.47	
For details of inventories pledged, refer Note 16.			
8 Trade receivables		As at	As at
Particulars	31 March 2026	31 March 2025	
Current (Unsecured)			
Considered good	4,470.15	3,164.36	
Less: Loss allowance	(665.47)	(546.25)	
Net trade receivables	3,804.68	2,618.11	
For details of trade receivables pledged, refer Note 16.			
The Company's exposure to credit and currency risks and loss allowances related to trade receivables are disclosed in Note 39			
8.1 Trade receivables ageing schedule		As at	As at
Particulars	31 March 2026	31 March 2025	
Undisputed trade receivables- considered good, unsecured			
Outstanding for following periods from due date of payment			
Not due	1,454.53	708.80	
Less than 6 months	1,989.13	1,613.08	
6 months - 1 year	678.89	559.03	
1-2 years	294.95	139.45	
2-3 years	29.77	51.04	
More than 3 years	22.88	72.96	
Total	4,470.15	3,164.36	



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

8.2 Loss allowance provision matrix- default rates applied at each reporting date

Particulars	As at 31 March 2026	As at 31 March 2025
Not due and Due date to 1 year	5% - 62%	9% - 16%
1-2 years	16% - 96%	16% - 91%
More than 2 years	100%	91% - 100%

8.3 Movement of loss allowance

Particulars	As at 31 March 2026	As at 31 March 2025
Balance at the beginning of the year	546.25	660.66
Add: Provision of loss allowance created during the year (Refer Note 30)	173.74	(114.41)
Less: Bad debts written off during the year	54.52	-
Balance at the end of the year	665.47	546.25

9 Cash and cash equivalents

Particulars	As at 31 March 2026	As at 31 March 2025
Balances with banks	88.31	23.92
-On current accounts	-	10.00
-Deposits with original maturity of less than three months	30.10	33.23
Cash on hand	118.41	67.15
Total		

10 Bank balances other than cash and cash equivalents above

Particulars	As at 31 March 2026	As at 31 March 2025
In deposit accounts (with original maturity of more than 3 months but less than 12 months)	-	21.00
Total	-	21.00

11 Loans

Particulars	As at 31 March 2026	As at 31 March 2025
Measured at amortised cost		
Non-current		
Unsecured, considered good	793.17	690.24
Dues from related parties (refer Note 37)	251.63	284.68
Others	1,044.80	974.92
Total		

12 Other financial assets

Particulars	As at 31 March 2026	As at 31 March 2025
Non-current		
Fixed deposits with banks #	307.83	348.77
Rent and other deposits*	4.35	6.57
Interest accrued on fixed deposits with banks	403.20	386.34
Total		
Current		
Unsecured, considered good	169.52	140.10
Unbilled receivables*	19.07	3.03
Rent and other deposits	505.17	426.09
Dues from related parties (refer Note 37)	29.19	-
Interest accrued on loan to related parties (Refer Note 17)	-	4.14
Interest accrued on fixed deposits with banks	0.34	-
Others	723.29	573.36
Total	1,126.49	959.70

* The above deposits are maintained against guarantees issued by Banks and are restricted for periods exceeding 12 months as at the Balance Sheet.

Includes deposits given to related parties, Refer Note 37

* Net of advance from patients of INR 64.19 lakhs (as at 31 March 2025: INR 102.48 lakhs).

13 Other assets

Particulars	As at 31 March 2026	As at 31 March 2025
Unsecured, considered good		
Non-current		
Prepaid expenses	18.31	24.40
Balance with government authorities	34.21	-
Advances for capital goods	51.34	110.41
Total	103.86	134.81
Current		
Prepaid expenses	61.27	99.16
Balance with statutory government authorities	4.50	25.36
Advance for supply of goods and services	131.79	159.25
Total	197.56	283.77
Total	301.42	418.58



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

14 Share capital Particulars	As at 31 March 2026		As at 31 March 2025	
	Number of shares	Amount	Number of shares	Amount
Authorised	1,10,00,000	1,100.00	1,10,00,000	1,100.00
Equity shares of INR.10 each	10,00,000	1,000.00	10,00,000	1,000.00
Redeemable preference shares of INR. 100 each	1,20,00,000	2,100.00	1,20,00,000	2,100.00
Issued, subscribed and fully paid-up	1,07,85,825	1,078.58	1,07,85,825	1,078.58
Equity shares of INR.10 each	1,07,85,825	1,078.58	1,07,85,825	1,078.58
Total				
Refer Notes 14.1 to 14.9 below				

14.1 Reconciliation of shares outstanding at the beginning and at the end of the reporting period Particulars	As at 31 March 2026		As at 31 March 2025	
	Number of shares	Amount	Number of shares	Amount
Equity shares of INR 10 each fully paid-up	1,07,85,825	1,078.58	1,07,85,825	1,078.58
Balance as at the beginning of the year	-	-	-	-
Issue of equity shares	1,07,85,825	1,078.58	1,07,85,825	1,078.58
Balance as at the end of the year				

14.2 Rights, preferences and restrictions attached to equity shares
The Company has a single class of equity shares. All equity shares rank equally with regard to dividends and share in the Company's residual assets. The equity shares are entitled to receive dividend as declared from time to time. The voting rights of an equity shareholder on a poll (not on show of hands) are in proportion to shareholders' share of the paid-up equity capital of the Company. Voting rights cannot be exercised in respect of shares on which any call or other sums presently payable have not been paid.

Failure to pay any amount called up on shares may lead to forfeiture of shares.

On winding up of the Company, the holders of equity shares will be entitled to receive the residual assets of the Company, remaining after distribution of all preferential amounts in proportion to the number of equity shares held.

14.3 Shares held by ultimate holding Company Particulars	As at 31 March 2026		As at 31 March 2025	
	Number of shares	Amount	Number of shares	Amount
Equity shares of INR 10 each fully paid-up held by Aster DM Healthcare Limited, Holding and Ultimate holding Company	76,02,928	760.29	62,00,771	620.08

14.4 Details of shareholders holding more than 5% shares of the Company Particulars	As at 31 March 2026		As at 31 March 2025	
	Number of shares	% of holding	Number of shares	% of holding
Equity shares of INR 10 each fully paid-up held by:				
Aster DM Healthcare Limited	76,02,928	70.49%	62,00,771	57.49%
Dr. P. Ramesh Babu	15,30,547	14.19%	21,46,404	19.90%
P. Mahalakshmi	5,00,000	4.64%	8,72,000	8.08%
P. Raja Nishanth	3,48,900	3.23%	5,67,000	5.26%
P. Madhusudha	5,10,000	4.73%	5,53,500	5.13%

14.5 Details of shareholding of Promoters Promoter name	Shares held as at 31 March 2026		Shares held as at 31 March 2025		Percentage change during the year ended 31 March 2026
	Number of shares	% of total shares	Number of shares	% of total shares	
Aster DM Healthcare Limited	76,02,928	70.49%	62,00,771	57.49%	13.00%
Dr. P. Ramesh Babu	15,30,547	14.19%	21,46,404	19.90%	-5.71%
P. Mahalakshmi	5,00,000	4.64%	8,72,000	8.08%	-3.45%
P. Raja Nishanth	3,48,900	3.23%	5,67,000	5.26%	-2.02%
P. Madhusudha	5,10,000	4.73%	5,53,500	5.13%	-0.40%
P. Mahendra Babu	1,73,000	1.60%	2,82,000	2.61%	-1.01%
P. V. Ravikishore	18,300	0.17%	40,000	0.37%	-0.20%
Madhumathi K.	28,900	0.27%	30,000	0.28%	-0.01%
P. Subba Rao	50,000	0.28%	30,000	0.28%	Nd
P. Murali Mohan	9,000	0.08%	20,000	0.19%	-0.10%
M. Saroja	9,000	0.08%	9,000	0.08%	Nd
P. Marmohan Krishna	6,400	0.06%	7,500	0.07%	-0.01%
P. Ashok Kumar	3,500	0.03%	4,400	0.04%	-0.01%
P. S. Kamala Devi	1,400	0.01%	2,500	0.02%	-0.01%
Dr. P. Vasundhara Devi	1,400	0.01%	2,500	0.02%	-0.01%
P. Madhuri	1,400	0.01%	2,500	0.02%	-0.01%
P. Padma Sree	1,400	0.01%	2,500	0.02%	-0.01%
P. Sri Lakshmi	1,400	0.01%	2,500	0.02%	-0.01%
Usha Rani Potuneni	1,400	0.01%	2,500	0.02%	-0.01%
Potun Gopi Krishna	1,150	0.01%	2,250	0.02%	-0.01%
R. Radha Devi	2,500	0.02%	2,500	0.02%	Nd
R. V. Chalapati Rao	2,500	0.02%	2,500	0.02%	Nd
M. S. Ramu Mohan Rao	1,100	0.01%	1,100	0.01%	Nd



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

14.6 Shares reserved for issue under options and contracts:

The Company has not reserved any shares for issuing under options and contracts.

14.7 Details of bonus shares issued during the past 5 years immediately preceding 31 March 2026:

The Company has not issued bonus shares during the period of five years immediately preceding 31 March 2026.

14.8 Details of shares issued for consideration other than for cash during the past 5 years immediately preceding 31 March 2026:

The Company has not allotted any equity shares as fully paid-up without consideration being received in cash during the past 5 years immediately preceding 31 March 2026.

14.9 Details of buyback of shares during the past 5 years immediately preceding 31 March 2026:

The Company has not brought back any shares during the past 5 years immediately preceding 31 March 2026.

15 Other equity

Particulars

**As at
31 March 2026**

**As at
31 March 2025**

Reserves and Surplus

Securities premium

7,454.54

7,454.54

- Used to record the premium received on issue of shares. It is utilised in accordance with the provisions of the Companies Act, 2013

40.00

40.00

Capital redemption reserve

- A statutory reserve created to the extent of sum equal to the nominal value of the share capital extinguished on buyback of Company's own shares pursuant to Section 69 of the Companies Act, 2013

7,491.83

6,175.28

Retained earnings

- Retained earnings comprises of the amounts that can be distributed by the Company as dividends to its equity share holders

(141.39)

(133.62)

Items of comprehensive income

Remeasurement of defined benefit liability (asset), net of tax

- Pertains to the remeasurement of the net defined benefit liability (asset) recognised net of tax

14,844.98

11,516.19

Total

(Intentionally left blank)



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2025
All amounts in INR lakhs, unless otherwise stated

16	Particulars	As at 31 March 2025	As at 31 March 2024
	Non-current		
	Secured - at amortised cost	1,266.00	1,809.24
	Term loans from banks (Refer notes below)	1,266.00	1,809.24
	Total		
	Current		
	Secured - at amortised cost		
	Cash credit and overdraft facilities from banks (Refer notes below)	125.61	312.76
	Current maturities of long term borrowings from banks (Refer notes below)	529.09	764.77
	Unsecured - at amortised cost		
	Loans from Subsidiary (Refer notes below)	330.08	76.65
	Total	984.78	1,154.18
	Total	2,250.78	2,963.42

Information about the Company's exposure to interest rate and liquidity risks are included in Note 19

A	Particulars	Details of loans as on 31 March 2025	Nature of Security
	Term loan 1	Loan o/s - INR 1.14 lakhs (31 March 2025 - INR 295.49 lakhs) Repayment terms- 84 monthly instalments	Primary Security: Equitable mortgage of lease hold rights on 304,302.47 Sq. Ft built up areas (3 cellars + Ground + 8 floors) on subleased land of 4,628.77 sq. fts. site in survey no. 1072, T.S.o:247/248, Ward no 17, Nagarampalem, Guntur. Secondary Security: Hypothecation of stock and book debts less than 180 days. Margins on stock and book debts are 25%. Corporate Guarantee of Lakshmana Hotels Pvt. Ltd.
	Term loan 2	Loan o/s - INR 1,276.52 lakhs (31 March 2025 - INR 1,625.32 lakhs) Repayment terms- 84 monthly instalments	Primary Security: Hypothecation of stock and book debts less than 180 days. Margins on stock and book debts are 25%. Secondary Security: EM on the Sanghamitra Building property situated at sy no.51/1A/1 va.yards 1800 and va.yards 1965, Sy.No.56/76 va.yards 564 at belluru village ongolo municipality, Ongole 523002 Corporate Guarantee of Lakshmana Hotels Pvt. Ltd.
	Term loan 3	Loan o/s - INR 521.74 lakhs (31 March 2025 - INR 653.20) Repayment terms- 60 monthly instalments	Primary Security: Equitable mortgage of lease hold rights on 304,302.47 Sq. Ft built up areas (3 cellars + Ground + 8 floors) on subleased land of 4,628.77 sq. fts. site in survey no. 1072, T.S.o:247/248, Ward no 17, Nagarampalem, Guntur. Secondary Security: Hypothecation of stock and book debts less than 180 days. Collateral Security: Mortgage of Land and Building at survey no. 1072, Nagarampalem, Guntur - 522004, T.Sno 247/248, Ward No. 1, Hyer Hall Corporate Guarantee of Lakshmana Hotels Pvt. Ltd.
	Bank Overdraft	Outstanding amount INR 125.61 lakhs (31 March 2025 - INR 132.76 lakhs)	Primary Security: Equitable mortgage of lease hold rights on 304,302.47 Sq. Ft built up areas (3 cellars + Ground + 8 floors) on subleased land of 4,628.77 sq. fts. site in survey no. 1072, T.S.o:247/248, Ward no 17, Nagarampalem, Guntur. Secondary Security: Hypothecation of stock and book debts less than 180 days. Collateral Security: Mortgage of Land and Building at survey no. 1072, Nagarampalem, Guntur - 522004, T.Sno 247/248, Ward No. 1, Hyer Hall Corporate Guarantee of Lakshmana Hotels Pvt. Ltd.

Interest rate on loans (including loan from subsidiary) ranges between 6.07% to 9.05% (31 March 2025 - 7.12% to 9.25%)

8 There are no constraints defaults in the repayment of the principal loan and interest amounts

17	Particulars	As at 31 March 2025	As at 31 March 2024
	Total outstanding dues of micro and small enterprises	660.21	264.41
	Total outstanding dues of creditors other than micro and small enterprises	2,427.70	2,147.13
	Total	3,087.91	2,411.54

All trade payables are current. The average credit period taken is 30-60 days.
The Company's exposure to currency and liquidity risks related to trade payables is discussed in Note 19

17.1	Particulars	Unsettled dues	Outstanding for following periods from due date of payment				Total*
			Less than 1 year	1-2 years	2-3 years	More than 3 years	
	Balance as at 31 March 2024						660.21
	Micro and small enterprises		1,59.90	0.05	0.26	-	1,60.21
	Others	261.38	2,077.90	24.74	54.16	4.52	2,427.78
	Total	261.38	2,737.80	24.79	54.42	4.52	3,087.91
	Balance as at 31 March 2025						264.41
	Micro and small enterprises		1,68.47	0.05	0.29	4.80	1,73.61
	Others	765.84	1,769.28	87.23	12.28	4.39	2,611.54
	Total	765.84	1,937.75	87.28	12.57	9.19	2,805.53



17.2 Disclosures as required under the Micro, Small and Medium Enterprises Development Act, 2006 ("the Act") based on the information available with the Company are given below:

Particulars	As at 31 March 2026	As at 31 March 2025
The principal amount remaining unpaid to any supplier at the end of the year	663.21	264.41
The interest due on the principal remaining outstanding as at the end of the year	-	-
The amount of interest paid under the Act, along with the amount of the payment made beyond the appointed day during the year	-	-

The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the Act

The amount of interest accrued and remaining unpaid at the end of the year

The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of discharge as a deductible expenditure under the Act

Note: The Ministry of Micro, Small and Medium Enterprises has issued an office memorandum dated 26 August 2008 which recommends that the Micro and Small Enterprises should mention in their correspondence with its customers the Entrepreneurship Memorandum Number as allocated after filing of the Memorandum. Accordingly, the disclosure in respect of the amounts payable to such enterprises as at 31 March 2026 has been made in the financial statements based on information received and available with the Company. Further in view of the management, the impact of interest, if any, that may be payable in accordance with the provisions of the Micro, Small and Medium Enterprises Development Act, 2006 ("The MSMED Act") is not expected to be material. The Company has not received any claim for interest from any supplier.

18 Other financial liabilities

Particulars	As at 31 March 2026	As at 31 March 2025
Non-current		
Securable deposits	37.00	37.00
Total	37.00	37.00
Current		
Interest accrued but not due on borrowings*	8.14	14.13
Dues to related party (Refer Note 17)	515.26	410.39
Interest accrued on loan from related party (Refer Note 17)	15.71	-
Dues to creditors for capital goods	347.39	713.62
Total	1,696.51	1,138.04

* The details of interest rates, repayment and other terms are disclosed in Note 16

The Company's exposure to currency and liquidity risk related to the above financial liabilities is disclosed in Note 19

19 Provisions

Particulars	As at 31 March 2026	As at 31 March 2025
Non-current		
Provision for employee benefits	993.76	756.65
Defined benefits obligation - Gratuity (refer Note 36)	993.76	756.65
Total	993.76	756.65
Current		
Provision for employee benefits	82.39	-
Compensated absences	82.39	-
Total	82.39	-

20 Other liabilities

Particulars	As at 31 March 2026	As at 31 March 2025
Current		
Statutory dues payable	237.43	245.49
Advance from patients	541.17	236.12
Total	820.40	531.81



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

21 Revenue from operations		
Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Revenue from hospital and medical services	24,396.93	22,518.55
Revenue from sale of pharmacy	2,828.67	2,668.98
Revenue from canteen	397.73	397.28
Other operating income	408.35	215.52
Total	28,031.68	25,800.33

The Company's revenue from other operating income comprises primarily of revenue from medical courses conducted at the hospital, income from revenue sharing agreements. Revenue from operations includes INR 30.69 lakhs (31 March 2025: INR 29.95 lakhs) from related parties. Refer Note 37.

(i) Category of customers		
Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Cash (Including Cards/Unified Payments Interface/wallets/bank transfer/Cheques)	14,911.99	15,090.64
Credit (Including CoPay)	12,313.61	10,096.89
Revenue from hospital and medical services and pharmacies	27,225.60	25,187.53
Others	806.08	612.80
Revenue from Operations	28,031.68	25,800.33

Nature of treatment		
Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
In- patient	19,653.26	18,066.40
Out- patient	4,743.67	4,452.15
Total (Revenue from hospital and medical services)	24,396.93	22,518.55

(ii) Reconciliation of revenue recognised with the contract price is as follows:

Healthcare services (Including other operating income)		
Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Contract price (as reflected in the invoice raised on the customer as per the terms of the contract with customer)	29,927.46	27,499.25
Reduction in the form of discounts and disallowances	(1,895.78)	(1,698.92)
Revenue recognised in the statement of profit and loss	28,031.68	25,800.33

(iii) Other operating income		
Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Revenue sharing arrangement	156.08	201.74
Others	252.27	13.78
Total	408.35	215.52

22 Other income		
Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Interest income		
on financial assets carried at amortised cost (Lease deposits)	9.16	7.17
on fixed deposits with banks	6.27	4.37
on others	84.82	73.50
Interest on income tax refund	-	24.02
Realised foreign exchange gain	-	1.24
Share of profit in limited liability partnership (Refer Note 37)	74.32	6.42
Gain on sale of investments (net)	0.54	0.11
Other non operating Income*	61.02	143.30
Total	236.13	260.13

* The company's other non-operating income primarily comprises guarantee commission, scrap sales and non-operating rental income. Other income includes INR 139.91 lakhs (31 March 2025: INR 56.67 lakhs) from related parties. Refer Note 37.



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

23 Purchases of medicines and medical consumables			
Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025	
Medicines and medical consumables	5,795.00	5,159.97	
Total	5,795.00	5,159.97	
Purchases of medicines and medical consumables includes INR 7.15 lakhs (31 March 2025: INR Nil) from related parties. Refer Note 37.			
24 Changes in inventories			
Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025	
Opening stock	508.47	504.06	
Closing stock	578.04	508.47	
Total	(69.57)	(4.41)	
25 Professional fees to consultant doctors			
Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025	
Professional fees to consultant doctors	6,268.17	5,725.05	
Total	6,268.17	5,725.05	
26 Lab outsourcing charges			
Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025	
Lab outsourcing charges	277.56	235.56	
Total	277.56	235.56	
Lab outsourcing charges includes INR 17.56 lakhs (31 March 2025: INR 17.64 lakhs) from related parties. Refer Note 37.			
27 Employee benefits expense			
Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025	
Salaries and allowances	7,509.66	6,563.16	
Contribution to provident and other funds (refer Note 36)	402.73	394.49	
Staff welfare expense	38.39	40.06	
Expenses related to post employment defined benefit plans (Refer Note 36)	185.14	147.40	
Total	8,135.92	7,145.11	
28 Finance cost			
Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025	
Interest on bank borrowings	195.37	248.74	
Interest on lease liabilities (refer Note 34)	326.60	344.79	
Other borrowing costs*	67.54	25.73	
Total	589.51	619.26	
*Finance costs includes INR 17.45 lakhs (31 March 2025: 30.72 lakhs) from related parties. Refer Note 37.			
29 Depreciation and amortisation			
Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025	
Depreciation on property, plant and equipment (refer note 4)	1,044.42	1,223.70	
Depreciation on right-of-use assets (refer note 34)	197.24	199.24	
Amortisation on intangible assets (refer note 5)	16.89	19.20	
Total	1,258.55	1,442.14	



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

30 Other expenses			
Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025	
Food and beverage	264.04	429.64	
Power, water and fuel	660.06	666.57	
Housekeeping, security and others	187.66	136.74	
Legal, professional and other consultancy	311.98	195.03	
Auditors remuneration (refer note 30.1)	17.56	17.01	
Rent (refer note 34)	120.49	109.62	
Repairs and maintenance - plant and machinery	482.45	609.86	
Repairs and maintenance - building	16.67	26.38	
Repairs and maintenance - Others	150.97	219.59	
Advertising and promotional	592.94	638.82	
Rates and taxes	156.16	145.88	
Allowances for credit losses on financial assets (refer note 8.3)	173.74	(114.41)	
Travelling and conveyance	188.60	162.27	
Loss on disposal of property, plant and equipment (net)	13.80	0.17	
Net loss on account of foreign exchange fluctuations	54.90	14.55	
Corporate social responsibility (refer note 30.2)	19.84	18.69	
Insurance	24.52	25.79	
Communication	68.51	76.58	
Office expenses	154.75	161.73	
Donation & charity	-	5.20	
Bank charges	70.30	59.70	
Bad debts written off	-	57.41	
Miscellaneous expenses	183.99	222.67	
Total	3,913.93	3,885.49	
30.1 Payment to auditors (net of goods and service tax)			
Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025	
For statutory audit	15.19	13.50	
For reimbursement of expenses	2.37	3.51	
Total	17.56	17.01	
30.2 Details of corporate social responsibility (CSR)			
Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025	
- Amount required to be spent by the Company during the year	19.84	18.69	
- Amount of expenditure incurred	19.84	18.69	
- Shortfall at the end of the year	-	-	
- Total of previous year shortfall	-	-	
- Reason for shortfall	Not applicable	Not applicable	
- Nature of CSR activities	Promoting healthcare, including preventive healthcare, eradicating hunger, poverty and malnutrition and promoting education including special education INR 19.84 lakhs (Maddipati Lakshmi Narayana Chowdary Memorial Trust)	Promoting healthcare, including preventive healthcare, eradicating hunger, poverty and malnutrition and promoting education including special education INR 18.69 lakhs (Maddipati Lakshmi Narayana Chowdary Memorial Trust)	
- Details of related party transactions			
- Whether provision is made with respect to a liability incurred by entering into a contractual obligation	Not applicable	Not applicable	
- Amount spent during the year on Construction/acquisition of an asset On purposes other than above	19.84	18.69	
Total	19.84	18.69	



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

30.3 Exceptional Items	For the year ended	For the year ended
Particulars	31 March 2026	31 March 2025
Impact of new Labour Codes #	251.41	-
Total	251.41	-

On 21 November 2025, the Government of India notified the four Labour Codes ('the New Labour Codes') - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 consolidating 29 existing labour laws. The Company has assessed and disclosed the incremental impact of these changes on the basis of best available information, consistent with the New Labour Codes and the guidance provided by the Institute of Chartered Accountants of India. The incremental impact in the year consists of provision for gratuity amounting to INR 145.52 lakhs, provision for compensated absences amounting to INR 82.39 lakhs and provision for overtime allowance amounting to INR 20.33 lakhs and towards incremental expense for PF and ESI amounting to INR 3.17 lakhs. This is primarily due to revision in wage definition. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the New Labour Codes and would make appropriate adjustments on the basis of such developments.



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

31 Income tax assets (net)

(a) Income tax assets/(liability)

Particulars	As at 31 March 2026	As at 31 March 2025
Income tax payments, including taxes withheld	1,670.66	758.73
Less: Provision made towards tax liabilities	(601.88)	(271.27)
Net income tax assets/(liability) at the end	1,068.78	487.46

(b) Amount recognised in statement of profit and loss

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Current tax	330.61	271.27
Current tax for earlier years	12.68	(11.52)
Deferred tax (including MAT credit entitlement)	187.49	310.52
Tax expense for the year	530.78	570.27

(c) Amount recognised in other comprehensive income

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Deferred tax	(3.19)	(30.95)
Tax expense/(income) for the year	(3.19)	(30.95)

(d) Reconciliation of effective tax rate

The standard rate of corporation tax applied to reported profit is 29.12 per cent (2024-25: 29.12 per cent).

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Profit before tax	1,847.33	1,851.29
Statutory income tax rate	29.12%	29.12%
Tax expenses/(asset)	537.94	539.39
Additional deduction on investment allowance	(96.14)	(35.17)
Non-deductible expenses/ permanent differences	5.77	(0.15)
Current tax for earlier years	12.68	-
Others	70.53	66.20
Income tax expense	530.78	570.27

(e) Recognised deferred tax assets and liabilities

(i) Deferred tax assets and liabilities are attributable to the following:

Particulars	As at 31 March 2026	As at 31 March 2025
Deferred tax asset	193.78	159.07
Provision for expected credit loss	313.08	220.36
Provision for employee benefits	450.18	446.39
On account of Right-of-use assets (ROU) and lease liabilities	150.60	441.67
Minimum Alternate Tax (MAT) credit entitlement receivable	1,107.64	1,269.49
Total deferred tax asset	2,114.28	2,336.98
Deferred tax liability	(811.40)	(788.92)
Excess of depreciation on property, plant and equipment under Income Tax Act, 1961 over depreciation under Companies Act	(811.40)	(788.92)
Total deferred tax liability	(811.40)	(788.92)
Deferred tax asset / (liability) (net)	296.24	480.57

The Company offsets deferred tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities related to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

31 Income tax assets (net) (continued)

(ii) Movement in temporary differences

Particulars	Balance as at 1 April 2025	Recognised through retained earnings	Recognised in Statement of Profit and Loss	Recognised through other comprehensive income	Balance as at 31 March 2026
Provision for expected credit loss	159.07	-	34.70	-	193.78
Provision for employee benefits	220.36	-	89.54	3.19	313.08
On account of ROU and lease liabilities	446.39	-	3.83	-	450.18
Minimum Alternate Tax (MAT) credit entitlement receivable	443.67	-	(293.07)	-	150.60
Excess of depreciation on property, plant and equipment under Income Tax Act, 1961 over depreciation under Companies Act	(788.92)	-	(22.48)	-	(811.40)
Net deferred tax liabilities	480.57	-	(187.49)	3.19	296.24

Particulars	Balance as at 1 April 2024	Recognised through retained earnings	Recognised in Statement of Profit and Loss	Recognised through other comprehensive income	Balance as at 31 March 2025
Deferred tax asset/(liabilities) in relation to:					
Provision for expected credit loss	183.79	-	(24.73)	-	159.07
Provision for employee benefits	184.69	-	4.71	30.95	220.36
On account of ROU and lease liabilities	427.73	-	18.65	-	446.39
MAT credit entitlement receivable	779.58	-	(335.91)	-	443.67
Excess of depreciation on property, plant and equipment under Income Tax Act, 1961 over depreciation under Companies Act	(815.69)	-	26.76	-	(788.92)
Total deferred tax asset/(liability)	760.10	-	(310.51)	30.95	480.57

(iii) Deferred tax assets not recognised on grounds of prudence- Nil

(f) Tax losses carried forward - Nil



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

32	Contingent liabilities and commitments Particulars	As at	As at
		31 March 2026	31 March 2025
	Contingent liabilities		
	Claims against the Company not acknowledged as debts (Refer Note (h) below)	281.22	281.22
	Value Added Tax (Refer Note (c) below)	16.99	16.99
	Service tax (Refer Note (f) below)	39.80	-
	Income tax (Refer Note (g) below)	3.17	-
	Corporate guarantees to subsidiary (Refer Note 37)	428.46	450.18
	Commitments		
	Estimated amount of contracts remaining to be executed on capital account (net of advances) and not provided for	71.60	379.24

a. On 28th February 2019, the Hon'ble Supreme Court of India has delivered a judgment clarifying the principles that need to be applied in determining the components of salaries and wages on which Provident Fund (PF) contributions need to be made by establishments. Basis this judgment, the Company has re-computed its liability towards PF from the month of March 2019 and has paid PF as per Supreme Court judgement. In respect of the earlier periods/years, the Company has been legally advised that there are numerous interpretative challenges on the application of the judgment retrospectively. Based on such legal advice, the Management believes that it is impracticable at this stage to reliably measure the provision required, if any, and accordingly, no provision has been made towards the same. Necessary adjustments, if any, will be made to the books as more clarity emerges on this subject.

b. The Company does not have any long-term commitments or material non-cancellable contractual commitments/contracts, including derivative contracts for which there were any material foreseeable losses.

c. The Company was permitted to run a COVID Care Centre by the Krishna District Medical Health Officer in accordance with several measures undertaken by the Government of Andhra Pradesh after the outbreak of COVID-19 at Swarna Palace Hotel, Vijayawada. On 09 August 2020, a fire accident took place at Swarna Palace Hotel. A written report was submitted by the Tahsildar - Vijayawada East, at the Governorpet Police Station, Vijayawada regarding the said fire accident which was registered as FIR No.173 of 2020 of Governorpet Police Station, under Sections 304 (II), 308 read with 34 of IPC. FIR was filed against the Management of the Company and Swarna Palace Hotel. Several writ petitions have been filed by the Management of the Company to quash the proceedings in FIR No.173 of 2020; however, the investigations have been allowed to continue. Investigations are ongoing and the final report is yet to be filed. The Company has filed a discrimination petition against the Government in the Hon'ble High Court. The Company has reviewed this litigation and based on the legal advice, the Company believes that it is impracticable at this stage to reliably measure the amount of provision required, if any. The Company does not expect the outcome of these proceedings to have a materially adverse effect on its financial position.

d. The Company has reviewed all its pending litigations and proceedings and has adequately provided for where provisions are required and disclosed as contingent liability where applicable, in its financial statements. The Company does not expect the outcome of these proceedings to have a materially adverse effect on its financial position. The Company does not expect any reimbursement in respect of the above contingent liabilities.

e. The Company has received a demand order from the Commercial Taxes Department of Government of Andhra Pradesh in respect of Value Added Tax (VAT) pertaining to the financial years 2013-14, 2014-15 and 2015-16 based on the scrutiny carried out by the department. The Company is contesting the case and has paid INR 8.49 lakhs under protest in this regard.

f. The Company has received a demand order from the Office of the Commissioner of Central Tax (Guntur CGST Commissionerate) in respect of Service Tax pertaining to the financial years 2014-15, 2015-16 and 2016-17 based on the scrutiny carried out by the department. The Company is contesting the case and has paid INR 1 lakhs under protest in this regard.

g. The Company has received a demand order from the assessment unit at the Income Tax Department in respect of penalty under section 270A of the Income-tax Act 1961 pertaining to the financial year 2016 - 17 based on assessment proceedings completed under section 147 read with section 144B of the Income-tax Act 1961. The Company is contesting the case and INR 3.17 lakhs has been adjusted against refunds pending to be received for the financial year 2012-13.

h. The Company has reviewed all its pending litigations and proceedings and has adequately provided for where provisions are required and disclosed as contingent liability where applicable, in its financial statements. The Company does not expect the outcome of these proceedings to have a materially adverse effect on its financial position.



Dr. Ramesh Cardiac and Multispeciality Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

33 Earnings per share (EPS)

A. Basic earnings / (loss) per share

The calculation of profit/(loss) attributable to equity share holders and weighted average number of equity shares outstanding for the purpose of basic earnings / (loss) per share calculations are as follows:

i) Net profit/ (loss) attributable to equity share holders (basic)

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Net profit for the year, attributable to the equity share holders	1,316.55	1,282.02

ii) Weighted average number of equity shares (basic)

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Opening balance (refer Note 14)	1,07,85,825	1,07,85,825
Weighted average number of equity shares of INR 10 each for the year	1,07,85,825	1,07,85,825
Earnings per share, basic	12.21	11.89

B. Diluted earnings / (loss) per share

The calculation of profit / (loss) attributable to equity share holders and weighted average number of equity shares outstanding, after adjustment for the effects of all dilutive potential equity shares is as follows:

i) Net profit/ (loss) attributable to equity share holders (diluted)

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Net profit for the year, attributable to the equity share holders	1,316.55	1,282.02

ii) Weighted average number of equity shares (diluted)

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Weighted average number of equity shares of INR 10 each for the year (diluted)	1,07,85,825	1,07,85,825
Earnings per share, diluted	12.21	11.89

34 Lease liabilities and Right-of-use assets

The Company has taken land and buildings on lease from various parties from where the healthcare and management services are rendered. The leases typically run for a period of 1 year - 33 years. Lease payments are renegotiated nearing the expiry to reflect market rentals.

(i) Lease liabilities

Following are the changes in the lease liabilities for the year ended 31 March 2026 and 31 March 2025:

Particulars	As at 31 March 2026	As at 31 March 2025
Opening balance	3,989.08	3,820.25
Additions/Modifications/Reversals	(37.47)	345.00
Finance cost accrued during the period (refer Note 28)	326.60	344.79
Payment of lease liabilities	(519.50)	(520.96)
Closing balance	3,758.71	3,989.08
Non-current lease liabilities	3,569.70	3,821.25
Current lease liabilities	189.01	167.83

(ii) Maturity analysis – contractual undiscounted cash flows

Particulars	As at 31 March 2026	As at 31 March 2025
Less than one year	510.95	507.17
One to five years	2,157.37	2,144.94
More than five years	4,578.59	5,118.08
Total undiscounted lease liabilities	7,246.91	7,770.19



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

34 Lease liabilities and Right-of-use assets (continued)

(iii) Right-of-use assets

Right-of-use assets are presented on the balance sheet.

Particulars	As at 31 March 2026	As at 31 March 2025
Gross carrying value		
Opening balance	3,663.21	3,290.55
Addition/Modifications/Deletions to right-of-use assets	(46.17)	372.66
Total gross carrying value	3,617.04	3,663.21
Accumulated Depreciation		
Opening balance	1,207.04	1,007.80
Depreciation for the year (refer Note 29)	197.24	199.24
Total accumulated Depreciation	1,404.28	1,207.04
Net Balance	2,212.76	2,456.17

(iv) Amounts recognised in statement of profit or loss

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Lease rental expenses for lease where Ind AS 116 is not applicable (refer Note 30)	120.49	109.62
Interest on lease liabilities (refer Note 28)	326.60	344.79
Depreciation on right-of-use assets (refer Note 29)	197.24	199.24

(v) Amounts recognised in statement of cash flows

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Total cash outflow for leases	519.50	520.96

35 Segment reporting

Ind AS 108 "Operating Segment" ("Ind AS 108") establishes standards for the way that public business enterprises report information about operating segments and related disclosures about products and services, geographic areas, and major customers. Based on the "management approach" as defined in Ind AS 108, Operating segments are to be reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker (CODM). The CODM evaluates the Company's performance and allocates resources on overall basis. The Company's sole operating segment is therefore 'Medical and Healthcare Services'. Accordingly, there are no additional disclosure to be provided under Ind AS 108, other than those already provided in the financial statements.

The Company operates in India and revenue generations is from a wide spread of the customers and hence the disclosures of major customers are not applicable.



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

36 Employee benefits

a) Defined benefit plan

In accordance with Indian Law, the Company operates a scheme of gratuity which is a funded plan and the Company makes contributions to recognized funds in India. The gratuity plan provides for a lump sum payment to vested employees at retirement, death while in employment or termination of employment of an amount equivalent to 15 / 26 days' wages payable for each completed year of service, in accordance with the provisions under the Code of Social Security, 2020, as applicable. Vesting occurs upon completion of contractual period of continuous years of service or defined in Code on Social Security, 2020. The gratuity obligation is recognized subject to a maximum limit of INR 20,00,000.

Based on an actuarial valuation, the following table sets out the status of the gratuity plan and the amounts recognised in the Company's financial statements as at balance sheet date:

Following table sets out the status of employee benefits as at balance sheet date

Particulars	As at 31 March 2026	As at 31 March 2025
Present value of defined benefit obligation	1,168.75	904.81
Fair value of plan assets	(175.99)	(148.16)
Net liability recognised	992.76	756.65
Current	-	-
Non-current	992.76	756.65

A. Funding

The Company has purchased an insurance policy to provide for payment of gratuity to the employees. Every year, the insurance Company carries out a funding valuation based on the latest employee data provided by the Company. Any deficit in the assets arising as a result of such valuation is funded by the Company.

The following tables summarise the components of net benefit expense recognised in the statement of profit or loss and the funded status and amounts recognised in the balance sheet for the respective plans:

B. (i) Reconciliation of the fair value of defined benefit obligation

Particulars	As at 31 March 2026	As at 31 March 2025
Balance at the beginning of the year	904.81	717.88
Current service cost	136.46	103.77
Past service cost (Refer Note 30.3)	145.52	-
Interest cost	57.91	50.25
Benefits paid	(91.50)	(72.97)
Actuarial (gains)/ loss recognised in the other comprehensive income		
- experience adjustments	37.05	19.62
- changes in financial assumptions	(21.50)	86.26
Balance at the end of the year	1,168.75	904.81

(ii) Reconciliation of the fair value of plan assets

Particulars	As at 31 March 2026	As at 31 March 2025
Balance at the beginning of the year	148.16	54.07
Contributions paid into the plan by employer	105.50	160.85
Benefits paid	(91.50)	(72.97)
Interest income on plan assets	9.23	6.62
Actuarial gain/ (loss) on plan assets	4.60	(0.41)
Balance at the end of the year	175.99	148.16
Net defined benefit liability / (asset) (i-ii)	992.76	756.65
Current	-	-
Non-current	992.76	756.65

C. (i) Expense recognized in the Statement of profit and loss

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Current service cost	136.46	103.77
Past Service Cost	145.52	-
Interest cost	57.91	57.91
Interest income	(9.23)	(9.23)
	330.66	152.45

(ii) Remeasurements recognised in Other comprehensive income

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Actuarial (gain)/ loss on defined benefit obligation	15.55	105.88
Return on plan assets excluding interest income	(4.60)	0.41
	10.95	106.29



36 Employee benefits (continued)

D. Actuarial Valuation

The present value of the defined benefit obligation, and the related current service cost and past service cost, were measured using the

Investment risk	The present value of the defined benefit plan liability denominated in Indian Rupee is calculated using a discount rate determined by reference to market yields at the end of the reporting period on government bonds. For other defined benefit plans, the discount rate is determined by reference to high quality corporate bond yields when there is a deep market for such bonds; if the return on plan asset is below this rate, it will create a plan deficit. Currently the plan in India is investments in government securities and other debt instruments.
Interest rate risk	A decrease in the bond interest rate will increase the plan liability
Longevity risk	The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortality of plan participants both during and after their employment. An increase in the life expectancy of the plan participants will increase the plan's liability.
Salary risk	The present value of the defined benefit plan liability is calculated by reference to the future salaries of plan participants. As such, an increase in the salary of the plan participants will increase the plan's liability

(i) Assumptions used to determine benefit obligations:

Principal actuarial assumptions at the reporting date (expressed as weighted average)

Particulars	As at 31 March 2026	As at 31 March 2025
Financial assumptions		
Discount rate	6.70%	6.40%
Future salary growth rate	5.00%	5.00%
Attrition rate	10.00%	10.00%
Return on Plan assets	6.40%	7.00%
Retirement age	58 years	58 years
Weighted average duration of the obligation	6 years	7 years

Assumptions regarding future mortality experience are set in accordance with the published statistics by the Indian Assured Lives Mortality (IALM).

The Company assesses these assumptions with its projected long-term plans of growth and prevalent industry standards. The discount rate is based on the government securities yield.

Gratuity is applicable only to employees drawing a salary in Indian rupees and there are no other foreign defined benefit gratuity plans

ii) Sensitivity Analysis

Significant actuarial assumptions for the determination of the defined benefit obligation are discount rate, expected salary increase and

Particulars	31 March 2026		31 March 2025	
	Increase	Decrease	Increase	Decrease
Discount Rate (1% movement)	(66.62)	74.67	(54.84)	61.72
Future Salary Growth (1% movement)	75.19	(68.25)	61.96	(56.03)
Withdrawal rate (1% movement)	3.44	(4.10)	1.51	(1.97)

The sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligation as it is unlikely that the changes in assumptions would occur in isolation of one another as some of the assumptions may be correlated. In presenting the above sensitivity analysis, the present value of the defined benefit obligation has been calculated using the projected unit credit method at the end of the reporting period, which is the same as that applied in calculating the defined benefit obligation liability recognised in the balance sheet. There was no change in the methods and assumptions used in preparing the sensitivity analysis from prior years.

(iii) The Company has to pay Nil (31 March 2025: Nil) as contribution towards its defined benefit obligation in the next financial year.

b) Defined contribution plan

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Contribution to Provident Fund	312.19	306.06
Employee State Insurance	88.59	58.43
Labour welfare fund	1.95	-
Components recognised in the statement of profit and loss	402.73	394.49



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

37 Related parties

(i) Names of related parties and description of relationship with the Company:

- (a) Holding Company
(b) Subsidiary Company
(c) Fellow subsidiaries
(d) A trust wherein the directors of the Company and their relatives are trustees
- Aster DM Healthcare Limited
Aster Ramesh Duhita LLP
Sanghamitra Hospitals Private Limited
Komali Fertility Centre LLP
Komali Fertility Centre LLP-Ongole
Adiran IB Healthcare Private Limited
Aasraya Healthcare LLP
Sri Sainatha Multispecialty Hospitals Private Limited
Maddipati Lakshmi Narayana Chowdary Memorial Trust

(e) Key managerial personnel (KMP)

- Dr. P. Ramesh Babu
Hemish Punshottam
Pavitra Pramod Humswadkar
Saggula Hari Krishna
- Managing Director
Company Secretary (till 17 October 2024)
Company Secretary (w.e.f. 15 April 2025)
Chief Financial Officer (till 27 January 2026)

(f) Other Non Executive Directors

- Thadathil Joseph Wilson
Devanand Kolothodi (till 19 July 2025)
Sunil Kumar M R
Ramesh Kumar S (w.e.f. 17 Oct 2024)
Prashanth Nagaraja (w.e.f. 10 September 2025)
P. Raja Nishant
M S. Rama Mohan Rao (Chairman and Director)
- Nerendranath Venkataschala
Sri Krishna Nuthalapeti

(g) Relatives of KMP

- P. Subba Rao
P S Kamala Devi
P. Madhumitha
P. Mahendra Babu
Madhumathi K
Dr. P. Vasundhara Devi
P. Madhuri
R. V. Chalapathi Rao
R. Radha Bai
M. Sailaja
P. Mahalakshmi
P V Ravikishore
P. Murali Mohan
- Father of Managing Director
Mother of Managing Director
Daughter of Managing Director
Brother of Managing Director
Sister of Managing Director
Sister of Chairman and Director
Wife of P. Mahendra Babu
Father in law of Managing Director
Mother in law of Managing Director
Daughter-in-law of Chairman
Wife of Managing Director
Brother of Managing Director
Brother of Managing Director

(ii) Related party transactions:

The Company has entered into the following transactions with related parties during the year ended 31st March 2026:

Transactions with key managerial persons including Directors:

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
Rent expense	48.85	50.68
Short term employee benefits*	355.09	256.59

* The above figure does not include provision for gratuity as the same is determined for the Company as a whole based on an actuarial valuation.

Balances receivable / (payable) with key managerial persons including Directors:

Particulars	Name of the Related Party	As at 31 March 2026	As at 31 March 2025
Rent deposit*	Dr. P. Ramesh Babu	23.25	26.25

* Actual payout done towards the rent deposit.



Dr. Ramiah Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

37 Related parties (continued)

Transactions with related parties other than key managerial persons :			
Particulars	Name of the Related Party	For the year ended 31 March 2026	For the year ended 31 March 2025
Rent expense	P. Mahalakshmi	15.84	15.43
	Dr. P. Vasundhara Devi	48.85	48.85
	P.S. Kamala Devi	24.43	24.43
	K. Madhumathi	48.85	48.85
	M. Sailaja	33.71	31.51
	P. Murali Mohan	12.21	12.21
	P.V.Ravi Kishore	12.21	12.21
	Total	196.10	193.51
Other medical services income	Komali fertility Centre LLP	16.90	18.67
Expenses incurred by Holding Company on behalf of subsidiary	Komali fertility Centre LLP	4.10	49.45
	Total	20.99	68.12
Expenses incurred by Holding Company on behalf of subsidiary	Aster DM Healthcare Limited, India	129.61	117.21
Lab services received	Aster DM Healthcare Limited, India	17.56	17.64
	Total	147.17	134.85
Expenses incurred by Holding Company on behalf of subsidiary	Sanghamitra Hospitals Private Limited	23.29	16.74
Purchases other than medicines	Sanghamitra Hospitals Private Limited	7.15	-
Lab services given	Sanghamitra Hospitals Private Limited	13.80	11.28
Professional services given	Sanghamitra Hospitals Private Limited	77.86	93.86
Loan taken from subsidiary (net)	Sanghamitra Hospitals Private Limited	390.00	49.00
Interest on loan from subsidiary	Sanghamitra Hospitals Private Limited	17.45	30.72
	Total	529.55	201.60
Loan given to subsidiary (net)	Adiran IB Healthcare Pvt Ltd	162.30	173.39
Interest on loan to subsidiary	Adiran IB Healthcare Pvt Ltd	60.69	44.71
Guarantee commission income received	Adiran IB Healthcare Pvt Ltd	4.90	5.54
Expenses incurred by Holding Company on behalf of subsidiary	Adiran IB Healthcare Pvt Ltd	33.90	-
Professional services given	Adiran IB Healthcare Pvt Ltd	152.24	152.73
	Total	414.23	376.37
Expenses incurred by Holding company on behalf of subsidiary	Aasraya Healthcare LLP	9.27	-
	Total	9.27	-
Remuneration paid	Mrs P Mahalakshmi	9.00	9.00
	P. Madhu Smutha	5.88	5.88
	P. Mahendra Babu	54.00	42.84
	Total	68.88	57.72
Managerial Remuneration	Sitting fee	5.61	-
Expenses incurred by Holding company on behalf of subsidiary	Aster Ramesh Duhita LLP	0.09	-
Share of profit from associates & subsidiaries	Komali fertility Centre LLP	74.32	6.42
Donation/CSR given	Maddipati Lakshmi Narayana Chowdary Memorial Trust	19.84	18.69



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

37 Related parties (continued)

Balances receivable (payable) with related parties other than key managerial persons (contd.)

Particulars	Name of the Related Party	As at 31 March 2026	As at 31 March 2025
Other financial liabilities (Current) - Dues to related party & interest accrued on loan from related party	Aster DM Healthcare Limited	(505.48)	(410.28)
	Sanghamitra Hospitals Private Limited	(15.71)	-
	Komali Fertility Centre LLP	(9.80)	-
Financial assets - Other financial assets (current) - Dues from related parties & interest accrued on loan to related parties	Sanghamitra Hospitals Private Limited	36.33	87.23
	Komali Fertility Centre LLP	-	5.15
	Adiran IB Healthcare Pvt Ltd	425.85	259.78
	Komali Fertility Centre - Ongole LLP	26.37	26.38
	Aasraya Healthcare LLP	0.76	2.48
	Aster Ramesh Duhita LLP	45.07	45.07
Financial assets - Loans (current) - Dues from related parties	Adiran IB Healthcare Pvt Ltd	793.17	690.24
Financial liabilities- Borrowings- Loan from subsidiary	Sanghamitra Hospitals Private Limited	(330.00)	(76.65)
	Total	717.84	914.08
Financial assets - Other financial assets - Rent and other deposits	Mrs P. Mahalakshmi	5.61	5.61
	Dr. P. Vasundhara Devi	23.25	26.25
	P. Murali Mohan	5.81	6.56
	P. V. Ravi Kishore	5.81	6.56
	P. S. Kamala Devi	11.63	13.13
	K. Madhumathi	23.25	26.25
	P. Mahendra Babu	23.25	26.25
	Total	98.61	110.61
Managerial Remuneration payable	Short term employee benefits	-	7.40
	Total	-	7.40
Investment	Aster Ramesh Duhita LLP	47.75	47.75
	Komali fertility Centre LLP	40.00	40.00
	Sanghamitra Hospitals Private Limited	8,856.74	8,856.74
	Adiran IB Healthcare Pvt Ltd	160.63	160.63
	Komali Fertility Centre - Ongole LLP	51.00	51.00
	Aasraya Healthcare LLP	10.00	10.00
	Total	9,166.12	9,166.12
Guarantee given	Adiran IB Healthcare Pvt Ltd	428.46	450.18

38 Capital Management

The Company's policy is to maintain a stable capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Management monitors capital on the basis of return on capital employed as well as the debt to total equity ratio.

For the purpose of debt to total equity ratio, debt considered is long-term and short-term borrowings. Total equity comprise of issued share capital and all other equity reserves.

The capital structure as of 31 March 2026 and 31 March 2025 was as follows:

Particulars	As at 31 March 2026	As at 31 March 2025
Total equity attributable to the equity shareholders of the Company	15,923.56	14,614.77
As a percentage of total capital	73%	68%
Long-term borrowings including current maturities	1,795.09	2,574.01
Short-term borrowings	455.61	409.41
Non current lease liability	3,569.70	3,821.25
Current lease liability	189.01	167.83
Total borrowings	6,009.41	6,972.50
As a percentage of total capital	27%	32%
Total capital (Equity and Borrowings)	21,932.97	21,587.27



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

39 Financial Instruments - Fair value and risk management

A. Accounting classifications and fair values

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy.

31 March 2026

	Note	Carrying amount				Fair value			
		Mandatorily at FVTPL	Financial assets - Amortised cost	Other financial liabilities at amortised cost	Total Carrying value	Level 1	Level 2	Level 3	Total
Assets									
Financial assets measured at fair value									
Current investments	6	8.62	-	-	8.62	8.62	-	-	8.62
		8.62	-	-	8.62	8.62	-	-	8.62
Financial assets not measured at fair value									
Non-current investments	6	-	9,166.12	-	9,166.12	-	-	-	-
Trade receivables	8	-	3,804.68	-	3,804.68	-	-	-	-
Cash and cash equivalents	9	-	118.41	-	118.41	-	-	-	-
Loans	11	-	1,044.80	-	1,044.80	-	-	-	-
Other Financial Assets	12	-	1,126.49	-	1,126.49	-	-	-	-
Total			15,260.50	-	15,260.50	-	-	-	-
Liabilities									
Financial liabilities not measured at fair value									
Borrowings	16	-	-	2,250.70	2,250.70	-	-	-	-
Lease liabilities	34	-	-	3,758.71	3,758.71	-	-	-	-
Trade payables	17	-	-	3,087.91	3,087.91	-	-	-	-
Other financial liabilities	18	-	-	1,123.51	1,123.51	-	-	-	-
Total			-	10,220.83	10,220.83	-	-	-	-

31 March 2025

	Note	Carrying amount				Fair value			
		Mandatorily at FVTPL	Financial assets - Amortised cost	Financial liabilities - amortised cost	Total Carrying value	Level 1	Level 2	Level 3	Total
Financial assets measured at fair value									
Current investments	6	8.08	-	-	8.08	8.08	-	-	8.08
		8.08	-	-	8.08	8.08	-	-	8.08
Financial assets not measured at fair value									
Non-current investments	6	-	9,166.12	-	9,166.12	-	-	-	-
Trade receivables	8	-	2,618.11	-	2,618.11	-	-	-	-
Cash and cash equivalents	9	-	67.15	-	67.15	-	-	-	-
Bank balances other than cash and cash equivalents above	10	-	21.00	-	21.00	-	-	-	-
Loans	11	-	974.92	-	974.92	-	-	-	-
Other Financial Assets	12	-	959.70	-	959.70	-	-	-	-
Total			13,807.00	-	13,807.00	-	-	-	-
Financial liabilities not measured at fair value									
Borrowings	16	-	-	2,983.42	2,983.42	-	-	-	-
Lease liabilities	34	-	-	1,989.08	1,989.08	-	-	-	-
Trade payables	17	-	-	2,611.54	2,611.54	-	-	-	-
Other financial liabilities	18	-	-	1,175.04	1,175.04	-	-	-	-
Total			-	10,759.08	10,759.08	-	-	-	-



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

39 Financial instruments - Fair values and risk management (continued)

B Financial risk management

The Company's activities expose it to a variety of financial risks: credit risk, market risk and liquidity risk.

i) Risk management framework

The Company's board of directors has overall responsibility for the establishment and oversight of the risk management framework.

The Company's audit committee oversees how management monitors compliance with the risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. The Board is assisted in its oversight role by internal audit. Internal audit undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to the audit committee.

ii) Credit risk

Credit risk is the risk that the counterparty will not meet its obligation under a financial instrument or customer contract, leading to financial loss. The credit risk arises principally from its operating activities (primarily trade receivables) and from its investing activities, including deposits with banks and other financial instruments.

Credit risk is controlled by analysing credit limits and creditworthiness of customers on a continuous basis to whom credit has been granted after obtaining necessary approvals for credit. The collection from trade receivables are monitored on a continuous basis by the receivables team.

The Company always measures the loss allowance for trade receivables at an amount equal to lifetime ECL. The expected credit losses on trade receivables are estimated using a provision matrix by reference to past default experience of the debtors and an analysis of the debtors' current financial position, adjusted for factors that are specific to the debtors, general economic conditions of the industry in which the debtors operate, and an assessment of both the current as well as the forecast direction of conditions at the reporting date.

The maximum exposure to the credit risk at the reporting date is primarily from trade receivables amounting to INR 3,804.68 lakhs (31 March 2025: INR 2,618.11 lakhs) and unbilled receivables (net of advances from patient) as given in note 12 amounting to INR 169.52 lakhs (31 March 2025: INR 140.10 lakhs)

The movement in lifetime ECL in respect of trade and other receivables during the year was as follows:

	As at 31 March 2026	As at 31 March 2025
Allowance for credit loss	546.25	660.66
Balance at the beginning	173.74	(114.41)
Provision of loss allowance (Refer Note 30)	54.52	-
Bad debts written off	665.47	546.25
Balance at the end		

No single customer accounted for more than 10% of the revenue as of 31 March 2026 and 31 March 2025. There is no significant concentration of credit risk.

Credit risk on cash and cash equivalent and other bank balances is limited as the Company generally transacts with banks with high credit ratings assigned by international and domestic credit rating agencies.



39 Financial Instruments - Fair values and risk management (continued)

- (ii) **Liquidity risk**
Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. Ultimate responsibility for liquidity risk management rests with the board of directors, which has established an appropriate liquidity risk management framework for management of the Company's short, medium and long-term funding and liquidity management requirements. The Company's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of 31 March 2026:

Particulars	Less than 1 Year	More than 1 year	Total
Trade payables	3,087.91	-	3,087.91
Current borrowings	984.70	-	984.70
Non current borrowing	-	1,266.00	1,266.00
Lease liabilities	510.95	6,735.96	7,246.91
Other financial liabilities	1,086.51	37.00	1,123.51
Total	5,670.07	8,038.96	13,709.03

The Company is using the cash inflows from the financial assets and the available bank facilities to manage the liquidity. The table below provides the cash inflows from significant financial assets as of 31 March 2026:

Particulars	Less than 1 year	More than 1 year	Total
Cash and Cash equivalents	118.41	-	118.41
Investments	8.62	9,166.12	9,174.74
Trade receivables	3,804.68	-	3,804.68
Loans	1,044.80	-	1,044.80
Other financial assets	723.29	403.20	1,126.49
Total	5,699.80	9,569.32	15,269.12

The table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of 31 March 2025:

Particulars	Less than 1 Year	More than 1 year	Total
Trade payables	2,611.54	-	2,611.54
Current Borrowings	1,174.18	-	1,174.18
Non current borrowings	-	1,809.24	1,809.24
Lease liabilities	507.17	7,263.02	7,770.19
Other financial liabilities	1,178.04	37.00	1,215.04
Total	5,430.93	9,109.26	14,540.19

The Company is using the cash inflows from the financial assets and the available bank facilities to manage the liquidity. The table below provides the cash inflows from significant financial assets as of 31 March 2025:

Particulars	Less than 1 year	More than 1 year	Total
Cash and Cash equivalents	67.15	-	67.15
Bank balances other than cash and cash equivalents above	21.00	-	21.00
Investments	8.08	9,166.12	9,174.20
Trade receivables	2,618.11	-	2,618.11
Loans	974.92	-	974.92
Other financial assets	573.36	386.34	959.70
Total	4,262.62	9,552.46	13,815.08

Financial assets of INR 15,269.12 lakhs as at 31 March 2026 is in the form of cash and cash equivalents, investments, trade receivables, loans and other financial assets where the Company has assessed the counterparty credit risk. Trade receivables of INR 3,804.68 lakhs (net of provision of INR 665.47 lakhs) as at 31 March 2026 carried at amortised cost and is valued considering provision for allowance using expected credit loss method (if any). In addition to the historical pattern of credit loss, we have considered the likelihood of increased credit risk. The Company has specifically evaluated the potential impact with respect to Healthcare service sector. The Company closely monitors its customers who are being impacted. Also a substantial portion of the financial asset is related to investments in subsidiaries (INR 9,166.12 lakhs) and loans to subsidiary and others (INR 1,044.80 lakhs) wherein Management has considered on the projections while doing its assessment for impairment testing.

Financial assets of INR 13,815.08 lakhs as at 31 March 2025 is in the form of cash and cash equivalents, bank balances other than cash and cash equivalents, investments, trade receivables, loans and other financial assets where the Company has assessed the counterparty credit risk. Trade receivables of INR 2,618.11 lakhs (net of provision of INR 546.25 lakhs) as at 31 March 2025 carried at amortised cost and is valued considering provision for allowance using expected credit loss method (if any). In addition to the historical pattern of credit loss, we have considered the likelihood of increased credit risk. The Company has specifically evaluated the potential impact with respect to Healthcare service sector. The Company closely monitors its customers who are being impacted. Also a substantial portion of the financial asset is related to investments in subsidiaries (INR 9,166.12 lakhs) and loans to subsidiary and others (INR 974.92 lakhs) wherein Management has considered on the projections while doing its assessment for impairment testing.

- (iv) **Market risk**
Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices, such as foreign exchange rates, interest rates and equity prices.

- (v) **Interest rate risk**
The Company is exposed to interest rate risk because the Company borrows funds at both fixed and floating interest rates. The Company's significant interest rate risk arises from long-term borrowings with variable interest rates, which expose the Company to cash flow interest rate risk. The interest rate on the Company's financial instruments is based on market rates. The Company monitors the movement in interest rates on an ongoing basis. The risk is managed by the Company by maintaining an appropriate mix between fixed and floating rate borrowings.

The exposure of the Company's borrowing to interest rate changes at the end of the reporting period are as follows:

Financial liabilities	31 March 2026	31 March 2025
Variable rate long term borrowing including current maturities and overdraft	2,350.70	2,953.42



19 Financial Instruments - Fair values and risk management (continued)

Sensitivity analysis	Impact on profit or (loss)		Impact on equity, net of tax	
	31 March 2026	31 March 2025	31 March 2026	31 March 2025
Particulars				
1% increase in MCLR rate	(22.51)	(29.83)	(22.51)	(29.83)
1% decrease in MCLR rate	22.51	29.83	22.51	29.83

The analysis is prepared assuming the amount of liability outstanding at the reporting date was outstanding for the whole year. A one per cent increase or decrease is used when reporting interest rate risk internally to key management personnel and represents management's assessment of the reasonably possible change in interest rates. The Company's sensitivity to interest rates has increased in the current year due to the additional variable rate long term borrowings taken during the year.

- vi) Foreign currency risk
Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rate. The majority of the Company's assets are located in India and Indian rupee being the functional currency for the Company. The Company's exposure to the risk of changes in foreign exchange rates is minimal and not significant.

The Company undertakes transactions denominated in foreign currencies; consequently, exposures to exchange rate fluctuations arise. The Company is mainly exposed to US dollar. The carrying amounts of the Company's foreign currency denominated monetary assets and monetary liabilities at the reporting date are as follows.

	As at March 31, 2026	As at March 31, 2025
USD		
Other current financial liabilities	-525.34	-661.14

Sensitivity analysis

The sensitivity of profit or loss to changes in exchange rates arises mainly from foreign currency denominated financial instruments. One per cent is the sensitivity rate used when reporting foreign currency risk internally to key management personnel and represents management's assessment of the reasonably possible change in foreign exchange rates. The sensitivity analysis includes only outstanding foreign currency denominated monetary items and adjusts their translation at the year-end for a one per cent change in foreign currency rates. A positive number below indicates an increase in profit and other equity where currency units strengthens one per cent against the relevant currency. For a one per cent weakening of currency units against the relevant currency, there would be a comparable impact on the profit and other equity, and the balances below would be negative.

Particulars	Impact on profit or (loss)		Impact on equity	
	As at 31 March 2026	As at 31 March 2025	As at 31 March 2026	As at 31 March 2025
INR/ USD - Increase by 1%	-5.25	-6.61	-5.25	-6.61
INR/ USD - Decrease by 1%	5.25	6.61	5.25	6.61



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

40 Investments, loans, guarantees and security

(a) The Company has made investment in the following companies / limited liability partnerships:

Particulars	As at 1 April 2025	Allotment/Purchases during the year	Sold during the year	Impairment/ Write off	As at 31 March 2026
Investment in equity instruments	47.75	-	-	-	47.75
Aster Ramesh Duhita LLP	8,856.74	-	-	-	8,856.74
Sanghamitra Hospitals Private Limited	40.00	-	-	-	40.00
Komali Fertility Centre LLP	51.00	-	-	-	51.00
Komali Fertility Centre LLP-Ongole	160.63	-	-	-	160.63
Adiran IB Healthcare Private Limited	10.00	-	-	-	10.00
Ausraya HealthCare LLP	9,166.12	-	-	-	9,166.12
Total Investments					

Particulars	As at 1 April 2024	Allotment/Purchases during the year	Sold during the year	Impairment/ Write off	As at 31 March 2025
Investment in equity instruments	47.75	-	-	-	47.75
Aster Ramesh Duhita LLP	8,400.68	456.06	-	-	8,856.74
Sanghamitra Hospitals Private Limited	40.00	-	-	-	40.00
Komali Fertility Centre LLP	51.00	-	-	-	51.00
Komali Fertility Centre LLP-Ongole	160.63	-	-	-	160.63
Adiran IB Healthcare Private Limited	10.00	-	-	-	10.00
Ausraya HealthCare LLP	8,700.06	456.06	-	-	9,166.12
Total Investments					

(b) The Company has given unsecured loans to the following entities:

Entity	As at 1 April 2025	Movement	As at 31 March 2026	% of total loans	Purpose of loans
Subsidiary	690.24	102.93	793.17	75.92%	Financial assistance
Adiran IB Healthcare Private Limited					
Others	284.68	(33.05)	251.63	24.08%	Financial assistance
Dr. Ramesh Health and Educational Society					
Total	974.92	69.88	1,044.80	100.00%	

Entity	As at 1 April 2024	Movement	As at 31 March 2025	% of total loans	Purpose of loans
Subsidiary	476.04	214.20	690.24	70.80%	Financial assistance
Adiran IB Healthcare Private Limited					
Others	225.98	58.70	284.68	29.20%	Financial assistance
Dr. Ramesh Health and Educational Society					
Total	702.02	272.90	974.92	100.00%	

(c) The Company has given guarantees to the following entities:

Entity	As at 1 April 2025	Movement	As at 31 March 2026	% of total	Purpose of guarantee
Subsidiary	450.18	(21.72)	428.46	100.00%	Corporate guarantee given to HDFC Bank to give term loan and working capital loan
Adiran IB Healthcare Private Limited					
Total	450.18	(21.72)	428.46	100.00%	

Entity	As at 1 April 2024	Movement	As at 31 March 2025	% of total	Purpose of guarantee
Subsidiary	528.69	(78.51)	450.18	100.00%	Corporate guarantee given to HDFC Bank to give term loan and working capital loan
Adiran IB Healthcare Private Limited					
Total	528.69	(78.51)	450.18	100.00%	



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

- 41 The Company has established a comprehensive system of maintenance of information and documents as required by the transfer pricing legislation under sections 92-92F of the Income Tax Act, 1961. Since the law requires existence of such information and documentation to be contemporaneous in nature, the Company is in the process of updating the documentation for the international transactions expects such records to be in existence latest by the date of filing its income tax return as required by the law. The Management is of the opinion that its international transactions are at arm's length so that the aforesaid legislation will not have any impact on the financial statements, particularly on the amount of tax expense and that of provision for taxation.

42 Financial ratios	Ratio	Methodology (Refer Notes below)	As at		As at Variance (%)		Explanation if variance exceeds 25%
			31 March 2026	31 March 2025			
a)	Current ratio	Current assets/ Current liabilities	1.08	0.90	20%		Not applicable
b)	Debt-equity ratio	Total debt/ Shareholder's equity	0.37	0.47	-22%		Not applicable
c)	Debt service coverage ratio	Earnings available for debt service/ Debt service	1.97	2.86	-31%		Due to increase in inter-company borrowing
d)	Return on equity	Net profit after taxes/ Average shareholder's equity	8.62%	9.15%	-6%		Not applicable
e)	Inventory turnover ratio	Cost of goods sold/ Average inventory	10.54	10.78	3%		Not applicable
f)	Trade receivables turnover ratio	Revenue from operations/ Average accounts receivables	8.73	11.55	-24%		Not applicable
g)	Trade payables turnover ratio	Total purchases/ Average trade payables	2.03	1.84	10%		Not applicable
h)	Net capital turnover ratio	Net sales/ Working capital	60.38	(45.38)	-233%		Due to increase in trade receivables
i)	Net profit ratio	Net profit/ Net sales	4.70%	4.68%	0%		Not applicable
j)	Return on capital employed	Earnings before interest and taxes/ Capital employed	10.28%	10.28%	0%		Not applicable
k)	Return on investment	Dividend income, net gain on sale of investments and net fair value gain over average investments	0.81%	0.07%	1029%		Due to increase in dividend income during the year

Notes:

Total debt = Borrowings + Lease liabilities - Cash & cash equivalents - Current investments
Earnings available for debt service = Net profit before taxes + Non-cash operating expenses like depreciation and amortisations - Other income + Finance cost + Other adjustments (such as loss on sale of property, plant and equipment)
Debt service = Interest + Lease payments + Principal repayments
Net profit = Net profit after tax
Capital employed = Tangible net worth - Total debt
Earnings before interest and taxes = Net profit before taxes + Other income - Finance cost + Other adjustments (such as loss on sale of property, plant and equipment)

43 Additional disclosures

- a) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property during and as at 31 March 2026 and 31 March 2025 (the reporting periods).
- b) The Company has not revalued any of its Property, plant and equipment, Intangible assets and Right-to-use-assets during the reporting periods.
- c) There are no transactions and balances with companies which have been removed from the Register of Companies (struck off companies) during and as at the reporting periods.
- d) The Company has not traded or invested in Crypto currency during the reporting periods.
- e) The Company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies beyond the statutory period as at the reporting periods.
- f) The Company has not advanced or loaned or invested funds during the reporting periods to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
- Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
 - provide any guarantee, security or the like in or on behalf of the Ultimate Beneficiaries.
- g) The Company has not received any fund during the reporting periods from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
- directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
 - provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- h) The Company has no such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the reporting periods in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).
- i) The Company has not granted any loans or advances in the nature of loans to promoters, directors, KMPs and the related parties except note (j) below (as defined under Companies Act, 2013):
- repayable on demand; or
 - without specifying any terms or period of repayment.
- j) The Company has granted loan to Adran (B) Healthcare Pvt Ltd (refer Note 37) for business purpose which is repayable on demand at rate of interest 4.5% (31 March 2025: 8.5%).
- k) The Company is not declared as willful defaulter by any bank or financial institution (as defined under the Companies Act, 2013) or consortium thereof or other lender in accordance with the guidelines on willful defaulters issued by the Reserve Bank of India.



Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
Notes to the financial statements for the year ended 31 March 2026
All amounts in INR lakhs, unless otherwise stated

43 Additional disclosures (continued)

- n) The Company has complied with the number of layers for its holding in downstream companies prescribed under clause (87) of Section 2 of the Companies Act, 2013 read with the Companies (Restriction on number of Layers) Rules, 2017.
- m) The Company has used accounting softwares for maintaining its books of account for the year ended 31 March 2026 which have a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software except that in respect of accounting software used for maintenance of point of sales records wherein the audit trail was not enabled at the database level to log any direct data changes during the period from 1 April 2023 to 9 September 2025. Additionally, the audit trail that was enabled and operated for the year ended 31 March 2025, has been preserved by the Company as per the statutory requirements for record retention.



for and on behalf of the Board of Directors of
Dr. Ramesh Cardiac and Multispecialty Hospital Private Limited
CIN: U73100AP1995PTC020491

Ramesh Babu

Dr. P. Ramesh Babu
Managing Director
DIN: 01879436
Vijayawada
Date : 28 April 2026

M.S. Rama Mohan Rao

M.S. Rama Mohan Rao
Chairman and Director
DIN: 02356742
Vijayawada
Date : 28 April 2026

Pavitra Pramod Hunsawadkar

Pavitra Pramod Hunsawadkar
Company Secretary
Membership No. A73046
Vijayawada
Date : 28 April 2026

